

September 2016 - ISSUE 11

# WKMJ

World Korean Medical Journal



## Cover Story Inspirational Korean Healthcare Leader

Dr. Augustine M.K. Choi, Chairman of  
the Department of Medicine at  
Weill Cornell Medical College

## Entrepreneur Interview

Dr. Leon Reyfman, CEO of  
Advanced Clinical Laboratory Solutions, Inc


## Biopharmaceutical Report

FDA Review Policies For PD-1/PD-L1  
Inhibitors Spark Expert Debate

Democratizing Antibodies

NY-ESO-1 Therapy Renewed Enthusiasm  
Underscored By New Checkpoint Inhibitors

Photo credit: Roger Tully



**S-Vision Architecture and S-Vue Probe**

Consisting of the newly developed S-Vision Architecture and S-Vue probe, RS80A offers the state-of-the-art technologies for outstanding images.

# Advancing Therapeutics, Improving Lives.

For more than 25 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world.

Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Every day we strive to transform and simplify care for people with life-threatening illnesses.



## EXPERIENCE A TRULY PREMIER ULTRASOUND

RS80A increases professionalism and confidence with accurate results using advanced technologies developed by Samsung, while simultaneously enhancing user convenience and providing an effective work environment.

### RS80A PREMIUM AT ITS BEST



Scan code or visit  
[www.samsungmedison.com](http://www.samsungmedison.com)  
to learn more



For more information, please visit [www.gilead.com](http://www.gilead.com).  
© 2015 Gilead Sciences, Inc.

\* RS80A's approvals/registrations may differ by countries.



**SAMSUNG MEDISON**



Stay healthy and happy with GREEN CROSS CARE

# Green Cross to the world right now! Green Cross brings new hope to patients around the world



Since its establishment in 1967, Green Cross has consistently maintained a philosophy of taking the difficult but essential path, rather than the easier path. Now, Green Cross is going that extra mile by aiming to give new hope to people all around the world, not just those living in Korea. By combining its outstanding R&D capability for developing globally-recognized vaccines and blood derivatives with its differentiated solutions, Green Cross has set itself a new challenge to discover novel and much needed medicines and to become a trusted name, synonymous with protecting the health and happiness of people across the world.

**A global leader in the healthcare industry – Green Cross**



Children at the summer camp in Jeju Island, Korea. Elizabeth, Christopher, Jacob, Peter and Michael.

## OUR EDITORIAL BOARDS

**PUBLISHER** David Ko, MD

*Keck School of Medicine of Southern California*

**EDITOR IN CHIEF** Dohyun Cho, PhD

*W Medical Strategy Group*

**EDITORIAL BOARD**

Benjamin Lee, MD  
Chul S. Hyun, MD, PhD  
Han Choi, MD, LLM  
Han Kwang Yang, MD, PhD, FACS  
Hochang Lee, MD  
Hyung-kwon Kim, MD  
Hyunick Kim, MD  
Jinha Park, MD, PhD  
Joseph McMenamin, MD, JD  
Joshua Berlin  
Kimberly Ha  
Kyoung-Ryul Lee, MD, PhD  
Laura Carabello  
Lucie Siegel  
Mark Paxton, JD  
Querida Anderson  
Samuel Noh, PhD  
Stanley Shin, MD  
Tai P. Yoo, MD, MSBA, DLFAPA  
Yoon-kyo An, MD

*Sidra Medical and Research Center  
Weill Cornell Medical College  
Oracle Investment Management  
Seoul National University Hospital  
Yale School of Medicine  
Sociedade Beneficente Israelita Hospital Albert Einstein  
National Health Service of United Kingdom  
City of Hope Beckman Research Institute  
W Medical Strategy Group  
BioCentury  
FTI Consulting  
Hanaro Medical Foundation  
CPR Communications  
Bridge Global Strategies  
Rx-360 Consortium  
BioPharm Insight  
Psychiatry University of Toronto  
Statesboro Cardiology  
UCLA Kern Medical Center  
University of Queensland School of Medicine*

**PUBLICATION** W MEDICAL STRATEGY GROUP

**SECRETARIAT STAFF** Yisun Yuk / Yeereum Chung / Katie Lee / Sangji Lee / Eunie Kim /  
Minhye Park / Justin Brown / Sophia Emerson

**MAIN OFFICE** 210B Sylvan Ave., Tel. 201.402.1400  
Englewood Cliffs NJ 07632 Fax. 201.430.2472  
Email. info@wmedicalstrategy.org (Sophia Emerson)

**MEDIA PARTNERS**


World Korean Medical Journal is published bi-monthly by W Medical Strategy Group, 210B Sylvan Ave., Englewood Cliffs, NJ 07632. Tel. 201.402.1400, Fax. 201.430.2472, Email. info@wmedicalstrategy.org, Website www.wmedicalstrategy.org. Please send inquiries, subscription requests and address changes to the above address. Entire contents of this magazine are protected by copyright ©2016 WKMJ and may not be reproduced in whole or in part without express written consent. All rights reserved.

# WKMJ

World Korean Medical Journal

W K M J I I t h I s s u e W K M J  
I I t h I s s u e W K M J I I t h  
I s s u e W K M J I I t h I s s u e  
W K M J I I t h I s s u e W K M J  
I I t h I s s u e W K M J I I t h  
I s s u e W K M J I I t h I s s u e

Please send inquiries and subscription requests to  
[info@wmedicalstrategy.org](mailto:info@wmedicalstrategy.org)



## TABLE OF CONTENTS

- 05 OUR EDITORIAL BOARDS
- 07 TABLE OF CONTENTS
- 08 FROM THE PUBLISHER
- 09 FROM THE EDITOR-IN-CHIEF
- 11 WKMJ RECAP OF THE LAST ISSUE
- 14 COVER STORY  
Inspirational Korean Healthcare Leader  
Dr. Augustine M.K. Choi, Chairman of the Department of  
Medicine at Weill Cornell Medical College
- 22 ENTREPRENEUR INTERVIEW  
Dr. Leon Reyfman, CEO of  
Advanced Clinical Laboratory Solutions, Inc.
- 30 BIOPHARMACEUTICAL REPORT I  
FDA Review Policies for PD-1/ PD-L1 Inhibitors Spark Expert  
Debate
- 38 BIOPHARMACEUTICAL REPORT II  
Democratizing Antibodies
- 44 BIOPHARMACEUTICAL REPORT III  
NY-ESO-1 Therapy Renewed Enthusiasm Underscored by  
New Checkpoint Inhibitors
- 58 CONFERENCE ALERTS
- 64 BRIEF VIEW OF THE LATEST HEALTHCARE INDUSTRY



### Cover Story

Dr. Augustine M.K. Choi, Chairman of the  
Department of Medicine at  
Weill Cornell Medical College



### Entrepreneur Interview

Dr. Leon Reyfman, CEO of Advanced  
Clinical Laboratory Solutions, Inc.



### Biopharmaceutical Report

FDA Review Policies For PD-1/PD-L1  
Inhibitors Spark Expert Debate

Democratizing Antibodies

NY-ESO-1 Therapy Renewed Enthusiasm  
Underscored by New Checkpoint Inhibitors

## FROM THE PUBLISHER

Dear Colleagues,

I hope everyone had a great summer as the fall is just beginning. Serving as the president of the World Korean Medical Organization, this summer was very meaningful for me in that it held a forum in the Halls of US Congress. The meeting was featured in the past WKMJ issue on Global Health Disparities because of its innovativeness. Also in this summer, some Korean physicians met with Korean congress over the issue of limiting SSRI for depression by non-psychiatrist to 60 days and they sought out international opinion. We were able to help in that arena with Dr. Tai Yoo who organized Korean Mental Forum on prior WKMO meeting. Next year, we hope to hold a forum in Korea on various health issues.

In this 11th issue, WKMJ features a prominent Korean American physician Dr. Augustine Choi, who spoke at the World Korean Medical Organization meeting in New York a few years ago with many international Korean medical students. He specifically encouraged the students to find their passions and to pursue them. Dr. Choi is a Chairman and Professor of Cornell Medical Center Department of Internal Medicine. He is also a Physician in Chief of Weill Cornell Medical Center. He was recently appointed interim Dean and interim Provost of Weill Cornell Medical School of Cornell University. His interview highlights the triple threat of an academic physician as educator, researcher and clinician. Dr. Choi embodies all that but also the highest medical leadership that Deans and Provost hold in the University.

The entrepreneurial physician interview is with Dr. Leon Reyfman who is the CEO of Advanced Clinical Laboratory Solutions (ACLS). Laboratory testing is such an important facet of modern medical care and the need for rapid and cost effective testing is an area that he saw there was a need. ACLS has special expertise in drug testing and toxicology that has grown to be an epidemic problem and hopefully these tests will help practitioners and patients navigate appropriate drug use and avoid abuse. ACLS is also focusing on pharmacogenomics testing which is truly in the path of providing optimized individualized care.

In closing, this year's Presidential election process in America is a historic one for many reasons, including Dr. Ben Carson entering the fray and hopefully he will inspire other physicians to politics.



**David Y. Ko, MD**

Publisher  
President of WKMO  
Keck School of Medicine of USC

## FROM THE EDITOR-IN-CHIEF

After Eli Lilly announced their Open Innovation Drug Discovery (OIDD) platform several years ago, many multinational companies have adopted the idea of open innovation. Ideas, policies, strategies, and behaviors sometimes behave just like outbreaks of infectious disease. Malcolm Gladwell once wrote “they are social epidemics.” Couple of days ago, Allergen’s CEO Brent Saunders has stepped forward to issue the “Saunders Manifesto” on his Allergen CEO blog. Titled as “Our Social Contract with Patients”, Saunders’s commitments include fair pricing of drugs and enhancing accessibilities to medicines. If other companies follow Allergen’s lead, pharmaceutical industry can start to clean up its reputation and earn some respect from the world. Social epidemics and outbreaks in pharma world can be started following Saunders’s lead on transparency, accessibility, and innovation.

Through the edition 11 of WKMJ, we have interviewed another leader in therapeutic world, who has brought positive changes and synergistic model of science leadership. Dr. Augustine Choi, who is the Chairman of the Weill Cornell Medicine, Physician-in-Chief for New York-Presbyterian Hospital/Weill Cornell Medical Center, and dean for Cornell School of Medicine, showed us three major sectors in medicine - research, medical education, and clinical care - can be harmonized by well-orchestrated leadership. Dr. Choi shared his story and insight with our readers, and anticipated bright future by saying, “I am optimistic about the future of medicine as we work together with fellow researchers and physicians around the globe, so we may move forward, expand our horizon, and push our limits in caring for our communities.”

For the Entrepreneur Interview, we featured Dr. Leon Reyfman, CEO of Advanced Clinical Laboratory Solutions, Inc. who shared significant importance of toxicology testing to physicians and patients.

Addition to these two major articles, we have rich selection of articles which will bring amusement to our readers. Hoping to see more leadership like Saunders’ and Choi’s in the therapeutic world in near future.

Thank you.



**DoHyun Cho, PhD**

Editor in Chief  
President & CEO of W Medical Strategy Group  
Chairman of New York Health Forum

# OSONG Medical Innovation Foundation

To provide comprehensive and world class research infrastructure to support the research in developing high - tech medical technology

## New Drug Development Center

Provide supports for Global Bio medicine Development

## Medical Device Development Center

Provide world class comprehensive research space and system supporting the research in the areas of design, manufacturing and testing the development of high-tech medical devices

## Laboratory Animal Center

Fast-tracking the development of New Drugs and Medical Devices

## Clinical Trials Drug Manufacturing Center

Support the Commercialization of New Biopharmaceuticals Industry & Research Institutions

## WKMJ RECAP OF THE LAST ISSUE



### Cover Story Inspirational Korean Healthcare Leader “Dr. Kyung Sun, Chairman of Osong Medical Innovation Foundation”

Dr. Sun is currently Chief Director of Osong Medical Innovation Foundation since 2015. In the past, he served as a director of Korea Artificial Organ Center, a president of Korean Society of Medical and Biologic Engineering, and a chair of Board in Korean Society for Thoracic and Cardiovascular Surgery. Dr. Sun received an award for Health Industry Technology from Ministry of Health and Welfare in 2008 and National Medal for Presentation Order from Korean Government in 2013. Dr. Sun is a cardiovascular surgeon also serving as a professor at Korea University. To read more about Dr. Sun’s successful physician story, please read issue 10.

### Special Report Korea Rise: New Strategies Transforming Korean Biopharma Landscape

The Korean biopharma industry is mainly known for biosimilar and me-too products. But, as the Korean government investment and partnering money have begun to flow into the sector, a virtuous circle has been set in motion in which Korean biotechs are deploying a larger proportion of their revenues to R&D. That in turn is expected to lead to innovative products that could attract more multinationals to the partnering tables. VCs are also coming on board. In 2015 alone, venture investors poured \$270-\$260 million into Korean life sciences, compared to \$197 million in 2014 and \$166 million in 2013 according to Citi Asia Healthcare. To find out more about current Korean biopharma, please refer to issue 10.

### Biopharmaceutical Report I South Korea Trials Drive Further Opportunities for Global Pharma and CROs

South Korea’s foreign sponsor and CRO attraction over the last decade has scope to increase if it can improve capabilities in early-phase and complex trials, experts said. Clinical trial registration in South Korea shot up from 17 multinational-sponsored trials in 2002 to 296 in 2015, according to figures from Korea’s Ministry of Food and Drug Safety (MFDS). The US National Institutes of Health clinical trials database indicates 293 trials registered in Korea so far in 2016, and ranks South Korea first in Asia by number of protocols. Read issue 10 for more detailed report about current South Korea pharmaceutical trials.

### Biopharmaceutical Report II PCSK9 Inhibitor Competition: Amgen, Sanofi, and Regeneron Show Equally Decent CVOT Outcomes

Amgen’s (NASDAQ:AMGN) Repatha (evolocumab) and Sanofi (EPA: SAN)/Regeneron Pharmaceuticals’ (NASDAQ:REGN) Praluent (alirocumab) are expected to produce positive cardiovascular (CV) event outcomes in their respective CV outcomes trials (CVOTs), experts agreed. Previous post-hoc major cardiovascular event (MACE) analysis data and low-density lipoprotein-cholesterol (LDL-C) lowering outcomes inspires continued positive signal optimism for the PCSK9 inhibitors. Please read Issue 10 to find out more.



The Healthy day of  
world and  
we are  
here to make it happen

Since, 1983

It has been a 30 years of the craftsmanship that first to start and striving for the best preventive medicine practice and professional comprehensive medical examinations. It includes followings.

- Provides one-stop service from examination to treatment.
- Comprehensive Medical Exam/ National Health Insurance Examination/ Industrial Special Screening Examination
- Notified Center for Immigration Examinations, Student Visa Examinations, Work Visa Examinations
- Bioequivalence tests, Agency for Human Subject Right and Research
- Contracted for partnership with most of Prestige University Hospitals in Korea.

의료법인 하나로 의료재단 TEL: +82-2-590-1111  
Hanaro Medical Foundation URL: www.hanaromf.com



# ROCKPID®

The world first patented functional health food that modulates immunity  
PLAG in ROCKPID® has an immune modulating and immune balancing activity  
Hematopoietic, Anti-inflammatory and Anti-metastasis Efficacies  
Fulfills the popularization of deer antlers through state-of-the-art sciences and innovative technologies

Purchase is available @ [www.thepowerfood.com](http://www.thepowerfood.com)



## Inquiry

Email: [expert@enzychem.com](mailto:expert@enzychem.com) Tel: 1-800-611-9701

# INSPIRATIONAL KOREAN HEALTHCARE LEADER

## Weill Cornell Medical College Chairman of Medicine Augustine M.K. Choi, MD

*Dr. Augustine M.K. Choi (center) with research fellows (left) Drs. Ilias Siempos and Mitsuru Imamura. Photo credit: John Abbott*

### 1. What was your reason for attending medical school? Why did you want to become a physician?

- I was attracted to the field of Medicine because I wanted to help bring about positive impacts on the lives of people, especially concerning the quality of healthcare. My father, a brilliant physician as well as a great role model, was certainly the biggest influence in my decision to pursue medicine. Over the years, I watched my father serving the community through his medical practice, taking care of patients and people suffering from illnesses. I wanted to touch other's life in the same way he did. I never felt pressured to follow his paths; rather, my parents wanted us to find our own passion. My two siblings found their passion in their own field of choice, and I eventually found medicine as my life's work after considering a few different paths.

### 2. As a physician, you may have gone through various obstacles; can you share some of the most difficult moments during your career?

- Attending the medical school and training to become a physician requires commitment and dedication. It's not different from other professions that demand years of learning. It takes discipline, hard work and perseverance to be the best doctor one can be. During the four years of medical school, I rigorously absorbed and mastered many different skills and knowledge, after which, I was ready to interact with patients. During the medical residency, I realized that finding compassion and ways to truly care for a patient are not something you learn overnight. It is a life-long process; it does not stop after medical school.



*Dr. Augustine Choi and the Department of Medicine Celebrates its Voluntary Physicians at Griffis Faculty Club. From Left Drs. Arthur Radin (Hematology & Medical Oncology), Augustine M.K. Choi (Chairman, Department of Medicine), David S. Blumenthal (Cardiology) and Bruce Gordon (Rogosin Institute)*

### 3. You've been appointed as the Chairman of the Weill Cornell Medicine and Physician-in-Chief for New York-Presbyterian Hospital/Weill Cornell Medical Center. What are your responsibilities and principles of leading one of the most comprehensive academic and clinical departments in the country where physicians and research scientists focused on clinical care, research and medical education?

“One of my most important duties is shaping research landscape of the department. The Weill Cornell medicine is a hub for innovative biomedical research and clinical care, and it has a longstanding tradition of excellence.”

- The department of medicine is usually the largest unit in a medical school. Cornell is no exception. Weill Cornell Medicine is comprised of 16 divisions and more than 1,700 faculty members, physicians and research scientists focused on clinical care, research and medical education. Ever since I took the position as a chairman and physician-in-chief, I have directed and supervised clinical activities performed by each division. The Weill Cornell medicine covers wide variety of clinical services, including cardiology, clinical epidemiology, clinical pharmacology, emergency medicine, internal medicine and many more. It is also a home to more than 200 residents and fellows. It is also my responsibility to oversee medical education of the next generation of physicians and researchers. Speaking of research, one of my most important duties is shaping research landscape of the department. The Weill Cornell medicine is a hub for innovative biomedical research and clinical care, and it has a longstanding tradition of excellence. Though I am kept very busy due to various tasks at hand, it has been more than rewarding to participate in many successes the Weill Cornell medicine yielded over the years.

**4. What are some of the major performances and outcomes you have accomplished under your leadership? What are the long-term goals and visions you hope to see the Weill Cornell Medicine to achieve?**


- The Weill Cornell Medicine has three major missions: clinical care, medical education and research. For clinical care, I am proud to say that we are fortunate to host some of the best physicians in the world. What we offer doesn't stop with innovative and top of the line clinical techniques; it also includes intimate and compassionate care for our patients who need as much emotional support as clinical treatment. In medical education, we continue to train our medical students, residents and fellows to reach their full potential as doctors or researchers. In research, we have enriched our research portfolio and increased grant funding on many different areas including cancer, cardio vascular diseases, pulmonary diseases and herpetology at the Weill Cornell medicine. Personally, as a pulmonologist, I study chronic obstructive pulmonary disease (COPD). COPD is third leading cause of death in the United States following cancer and cardio vascular diseases. Despite the common perception, COPD does not develop from smoking in every case, non-smokers also develop COPD. There is no ultimate cure at this point, and current treatments have much room for improvement and continuing optimization. My research is to better understand the mechanism of COPD and to develop molecular targets for both diagnostics and therapeutics.



A ribbon-cutting ceremony officially opens the Jill Roberts Institute for Research in Inflammatory Bowel Disease's permanent laboratories at Weill Cornell Medicine. From left: Dr. Ellen Scherl, Jill Roberts, Dr. Augustine Choi, Jessica Bibliowicz and Dr. David Artis. Photo credit: Studio Brooke

**5. In the biomedical research, what are some significant changes or trends you have noticed in biomedical industry? What do you forecast the industry will be like in the next five years?**

- In the foreseeable future, biomedical research will empathize on translational research. The field will explore to find innovative methods of diagnostics and therapeutics. The objective is to utilize available technology to diagnose as early as possible in diseases process. It will allow doctors to intervene and treat patients in the earlier stages of diseases, which can increase effectively the success rate of the treatment. Secondly, National Institute of Health



Dr. Augustine M.K. Choi (center) with his laboratory team. Photo credit: Roger Tully

(NIH) funding has been decreasing throughout last decade. From 2003 to 2015, NIH lost 22% of its capacity to fund research due to budget cuts, sequestration, and inflationary losses. It means that biomedical research will not be able to rely solely on federal government funding. Importance of private sector funding will be inevitably amplified as result.

**6. What would be your advice or comments for current medical students as well as those who aspire to become a doctor?**

- The field of medicine can be a fulfilling career path for anyone because of its versatility. There are three major sectors in medicine: research, medical education, and clinical care. These three pillars of medical science cannot exist without the other. Regardless of one's choice to focus more on one over the others, the knowledge and experience one gain from any of these medical fields can be enormously helpful as you learn and practice medicine anywhere in the world. There are an infinite number of career paths to choose from; and in that search, the idea is to find and pursue what fits best your personality and aptitude. Medicine is definitely a rewarding and noble career for young people to explore given it has a wide and significant impact on the lives of many people, locally as well as globally. From an orthodontist to a heart surgeon, different professions of medicine all require different sets of skills and talents.

**7. WKMJ has readers from more than 10 countries globally. Please share your words or thoughts with our readers.**

- We are at the most exciting era of biomedical research. New discoveries are rapidly being made in both diagnostics and therapeutics. New approaches such as stem cell research and Nano-technology are opening new doors righto possibilities of treatments previously thought otherwise. I'm optimistic about the future of medicine as we work together with fellow researchers and physicians around the globe, so we may move forward, expand our horizon and push our limits in caring for our communities. **W**



Dr. Augustine Choi and his wife Dr. Mary E. Choi at W Medical Strategy Group event in Yale Club




### Augustine M.K. Choi, MD

Chairman, Department of Medicine at Weill Cornell Medical College  
Physician-in-Chief, New York Presbyterian/Weill Cornell Medical Center

Dr. Augustine M. K. Choi has been appointed chairman of the Department of Medicine at Weill Cornell Medical College and physician-in-chief at New York Presbyterian Hospital/Weill Cornell Medical Center. Dr. Choi is the Parker B. Francis Professor of Medicine at Harvard Medical School and chief of pulmonary and critical care medicine at Brigham and Women's Hospital in Boston. Dr. Augustine M.K. Choi is a clinician-scientist with expertise in the pathology and biology of lung disease. After receiving his medical degree from University of

Louisville, Dr. Choi served as an intern, resident and assistant chief resident in internal medicine at Duke University Medical Center. He then completed a fellowship in pulmonary and critical care medicine at Johns Hopkins University. Prior to joining Harvard and Brigham and Women's Hospital as chief of the Division of Pulmonary and Critical Care Medicine in 2007, Dr. Choi served on the faculty and medical staff of Johns Hopkins, Yale University and University of Pittsburgh, where he served as chief of pulmonary, allergy and critical care medicine. Dr. Choi has authored more than 235 peer-reviewed manuscripts and serves as the Associate Editor of the American Journal of Respiratory Cellular and Molecular Biology. He is a member of the American Society of Clinical Investigation and the Association of American Physicians.

Patients-centric, R&D-centric  
**KOREA UNIVERSITY MEDICAL CENTER**



Korea University Medical Center(KUMC) is establishing itself as the center of global medicine by achieving both balance and specialization in medical service, cutting edge digital technology and dedication to research

**“Striving to be the best medical complex”**

KUMC sets up the standards of Medicine education, Medical research, Medical service



College of Medicine  
의과대학  
(+82)-2-2286-1139



College of Health Science  
보건과학대학  
(+82)-2-940-2700



Anam Hospital  
안암병원  
(+82)-2-1577-0083



Guro Hospital  
구로병원  
(+82)-2-1577-9966



Ansan Hospital  
안산병원  
(+82)-2-1577-7516



# DAERIM SAINT MARY'S HOSPITAL

## Health Screening Program & Specialized Care Center

Experience the world class renowned medical services at Daerim St. Mary's Hospital, aim to become the world best.



### Global Healthcare Team

- The best specialist medical team, the most advanced medical technology and Impeccable service
- Optimized medical system for designing the best customized checkup program option for each patient

#### Appointment

08:30am~17:30pm 82-2-831-9003  
010-4557-5798 (kakao ID:Daerim8319003)  
Hoilday & At night 82-2-829-9222  
E-mail : global\_healthcare@drh.co.kr



# W MEDICAL STRATEGY GROUP

W Medical Strategy Group and its global network can lead your business to right solutions. Cruise on board with WMSG's in-depth expertise and accurate insights. We will navigate the world of health care industries to take you where you need to be.

Discover your destinations with us. Let the sailings begin.

[www.wmedicalstrategy.org](http://www.wmedicalstrategy.org)



**W Medical Strategy Group**  
210 (B) Sylvan Ave. Englewood Cliffs, NJ 07632  
Tel : (201) 402 – 1400 Fax : (201) 430 – 2472  
[www.wmedicalstrategy.org](http://www.wmedicalstrategy.org)

## CareStart™ G6PD Biosensor

World's First Quantitative Point-Of-Care Test

- Quantitative measurement
- True Point-Of-Care
- Results in just 4 minutes
- Store up to 1,000 test results
- CE marked



## CareStart™ HPV Genotyping & Screening Test

- **Real-time PCR**  
Qualitative diagnosis of high-risk HPV infections
- **Bead array**  
Multiplexing with precision detection of 33 HPV genotypes (15 high-risk and 18 low-risk), including 16 & 18



### Access Bio, Inc.

65 Clyde Road Suite A, Somerset, NJ 08873 U.S.A.  
Tel. +1 732-873-4040 E-mail. [info@accessbio.net](mailto:info@accessbio.net)

### Access Bio, Inc., Korea

B-1405, Gangseo Hangang Xii Tower, 401,  
Yangcehon-Ro, Gangseo-Gu, Seoul, South Korea  
Tel. +82 70-4739-3656



# Entrepreneur Interview

Entrepreneurial Physician Leads Fight Against Drug Epidemic  
Q&A with Leon Reyfman, M.D., CEO, Advanced Clinical Laboratory Solutions, Inc.

**1. We understand that Advanced Clinical Laboratory Solutions, Inc. (ACLS) is a rapidly growing laboratory testing company offering toxicology and pharmacogenetics testing services. What are the major business philosophies or strategies of ACLS?**

I began my career as a pharmacist, learning about drug dispensing and the challenges patients encountered with drug interactions, adverse events and drugs that simply did not work for certain people. In 2011, I set out to build the best laboratory services in the country. Today, ASCL is a state-of-the-art lab that reflects my mission to provide the highest quality of testing, expedient delivery of results, and superior customer service to clients throughout the United States. Our business philosophy is to stay ahead of innovations in toxicology and pharmacogenomics as the future of medicine.

We remain focused on turning around tests quickly and accurately, while being affordable and accessible to everyone, physicians and patients alike.

My passion for this business continues to grow – reinforced by such headlines as the recent story about 33 people who died from overdosing on synthetic marijuana in Brooklyn, my home territory. This rash of drug overdoses and spotlight on opioid abuse has underscored our driving strategy to give communities and individuals greater access to toxicology testing.

**2. How will you be positioned to compete with the large, high-profile lab companies?**

Independent clinical laboratories specializing in clinical toxicology and pharmacogenetics, like ACLS, are the best option for accessing convenient, high-quality testing services and accurate, timely test results. In fact, smaller labs are more responsive, and feature improved scheduling opportunities, faster turnaround of test results, accurate reporting and more competitive pricing.

This could make a vital difference for individuals in the U.S. and around the world who need addiction treatment.

Laboratory drug testing is critical for supporting clinicians, but with insurance costs on the rise, many of those suffering from addiction are unable to get full coverage for lab testing. Given the persistent and evolving introduction of new and highly dangerous drugs in communities, this kind of rapid drug testing as a primary prevention, diagnostic and monitoring tool can identify the presence or absence of drugs of abuse or therapeutic agents in multiple settings. Making lab testing more affordable and available across communities is essential for preventing drug abuse – and saving lives – especially among teens and young adults.



**3. Why is toxicology testing becoming so important for both physicians and their patients?**

The staggering statistics tell the story. Deaths from drug overdoses have risen in nearly every county across the United States, driven by an epidemic of addiction to prescription painkillers and heroin. The number of these deaths reached 47,055, a new peak, in 2014. In fact, the death rate from drug overdoses is climbing much more quickly than other causes of death.

One report found that much of the increase in opioid dependence occurred since 2011. Patients ages 19 to 35 were most likely to be diagnosed as opioid-dependent compared to other age groups.

As for physicians, accessible, reliable, and rapid testing enables them to get the information necessary to achieve the highest quality care and outcomes.

**4. We see that you have recently launched a healthcare advisory board. What was the motivation or inspiration behind this?**

ACLS formed a Business Advisory Board composed of healthcare luminaries and thought leaders as part of our commitment to providing convenient, high-quality testing services. These leaders and influencers share our passion for ending the country's heroin and opioid addiction crisis, and will help fuel our ongoing efforts.

Addiction to opioids and the use of street drugs, such as the K2, a synthetic marijuana, pose serious community issues that impact public health and social welfare, but clearly it is also a severe economic issue that affects everyone.

The primary diagnosis of opioid generates a number of medical services, including office visits, lab tests and other related treatments. In fact, the number of such services went from about 217,000 in 2007 to about seven million in 2014.

The Business Advisory Board will help spread this message among payers, healthcare providers and policymakers, who are well-advised to focus on insurance coverage that would enable these tests to be performed at smaller laboratory testing services.

**5. As an entrepreneur, what would you say are the top three priority assets or skill sets needed to be successful in the global healthcare industry?**

First of all, stay focused on innovation. Personalized medicine will be critical. This means being committed to finding the most optimal treatment regimen for each particular patient just by pinpointing the right drug at the right dose, for the right patient.

This ties into putting the patient first – the second important factor for success in the healthcare industry. This is essential across every area of healthcare. For example, our goal is to find the most effective and individualized balance at which a patient experiences maximum desirable analgesic relief and minimal undesirable adverse effects.

By initiating ongoing innovations for toxicology testing, labs like ACLS and others can implement more effective outreach, engagement, treatment, and coordination with the health and mental health systems and social supports.

Third, focus on the highest possible standards. For instance, ACLS is committed to medical research, quality and expedient testing that exceeds current standards of clinical toxicology because we want to do more than the bare minimum. We want to provide clients with the highest toxicology and clinical testing in the industry, including drug testing of urine and oral fluids, and pharmacogenetics for personalized prescribing. What we do matters. How we do it matters even more.

**6. WKMJ has readers from over 10 countries globally. Please share your final words or thoughts with our readers.**

I'd like to emphasize the value of pharmacogenomics testing-- identifying how genes affect a patient's response to medication. Genomic differences influence the efficacy of medication and can be the source of serious drug side-effects and increase the risk of drug-to-drug interactions. Pharmacogenetic testing is the alternative to one-size-fits-all drug prescribing, which can lead to potentially serious side effects, treatment failure and poor patient compliance.

Pharmacogenetic testing can also indicate which patients will be likely to experience adverse events with particular drugs – another application of particular interest to seniors, who often take multiple medications. Pharmacogenetic test results show how each particular medication is metabolized in the liver, providing each referring physician with a laboratory analysis of many of the patient's liver enzymes.

Along with the analysis, ACLS offers a detailed pharmacist's report that analyzes the patient's medication list and notes how it could be altered, based on information provided by the genomic test. People with certain genotypes have increased risk of life-threatening bleeds when introduced to the blood thinner warfarin or when dosages are changed. A dosing algorithm based on the patient's genotype can potentially thwart this risk.

Research has shown that maintaining steady levels of opioids contributes to pain relief, but patients metabolize pain medications at different rates. Slow metabolizers of opioids may sustain dangerously high levels of opioids in the body, resulting in adverse events. Personalized knowledge of a patient's metabolism patterns may assist in dosing.


Furthermore, pharmacogenetic test results may assist pain physicians in demonstrating that a particular patient requires a higher medication dose to experience pain relief. For example, for an ultra-rapid metabolizer, typical doses may not control pain for high metabolizers, who run the risk of being labeled abusers. [W](#)



**Leon Reyfman, M.D., FIPP, RpH**  
Chief Executive Officer, ACLS

Dr. Reyfman, chief executive officer, ACLS, is board-certified in Anesthesiology and Pain Management. He serves as director in Interventional Pain Medicine at Long Island College Hospital, and is assistant clinical professor of Anesthesiology at SUNY Downstate Medical School. Dr. Reyfman is a member of American Society of Interventional Pain Physicians, as well as the International Spine Intervention Society. He is actively involved in pain medicine research and teaching, has given multiple lectures in the areas of neuropathic pain, cancer pain, approach to diagnosis and treatment of lower back pain, and has extensive clinical experience and training in invasive and noninvasive pain management.

Award-Winning Journalist Team  
Exclusive Access to Newsmakers  
Unbiased Coverage  
Breaking News Every Day



# The Industry's Leading News Service

The award-winning BioPharm Insight journalist team delivers breaking news and insights on the life sciences industry every day. Our reporting is a must-have for decision makers at biopharmaceutical companies, CROs and service providers, and financial markets firms.

Part of the Mergermarket Group, the journalist team operates from New York, London, Washington DC, and Shanghai.

To learn more, email us at [hburke@biopharminsight.com](mailto:hburke@biopharminsight.com) or visit [www.biopharminsight.com](http://www.biopharminsight.com)



 **BioPharm Insight**

James V. Aiosa  
Paul V. Majkowski  
Geoffrey R. Kaiser  
Partners

 **RIVKIN RADLER**  
ATTORNEYS AT LAW

Driven to Deliver®

Long Island • New York City • New Jersey  
[www.rivkinradler.com](http://www.rivkinradler.com)

# A better option for clinical toxicology and pharmacogenetics testing.



Advanced Clinical Laboratory Solutions is an independent clinical laboratory specializing in clinical toxicology and pharmacogenetics that provides convenient, high-quality testing services and accurate, timely test results to patients, physicians and medical centers across the country.



844.225.7522 (844-ACLSLAB)



[www.aclsdiagnostics.com](http://www.aclsdiagnostics.com)

 YUYU TEIJIN MEDICARE INC.

## HOME OXYGEN THERAPY

## Home Care Service

### Renting home oxygen concentrators for patients with pulmonary diseases

Yuyu-Teijin Medicare Inc. is a home care service provider, improving the quality of care and quality of life for our customers in the home environment.

We focus on providing patient education and renting home oxygen concentrators to respiratory patients in Korea. Yuyu-Teijin Medicare was established in 2006 as a joint venture between Korea's Yuyu Pharma Inc ("Yuyu") and Japan's Teijin Pharma Ltd ("Teijin").

#### Oxygen Concentrator



3R



2U



3N



Vision Aire



Q5



Free Style



Focus

#### Pulse Oximeter



Finger



Tabletop



Handheld



ETCO2

YUYU TEIJIN MEDICARE INC.

Yuyu Building, 197 Dongho-ro, Jung-gu, Seoul, Korea +82-2-2253-6600 [www.yuyuteijin.co.kr](http://www.yuyuteijin.co.kr)



## BIOPHARMACEUTICAL REPORT I

FDA REVIEW POLICIES FOR PD-1/PD-L1 INHIBITORS SPARK EXPERT DEBATE



## BIOPHARMACEUTICAL REPORT II

DEMOCRATIZING ANTIBODIES



## BIOPHARMACEUTICAL REPORT III

NY-ESO-1 THERAPY RENEWED ENTHUSIASM UNDERSCORED BY NEW CHECKPOINT INHIBITORS

## Biopharmaceutical Report I

# FDA Review Policies for PD-1/PD-L1 Inhibitors Spark Expert Debate

The potential for changes to FDA oncology drug application review and approval policies has drawn contrasting expert opinions following comments by a high-ranking agency official bemoaning copious PD-1/PD-L1 inhibitors in development.

Comments made by Dr Richard Pazdur, Head of the FDA Office of Oncology, likely just reflect a personal desire for better company investment in other drug targets, several experts said. However, others said the agency could require larger studies and longer-term monitoring to discourage a crowded development space, as well as place me-too products on a lower review priority. Companies entering the space late still could leverage novel applications for PD-1/PD-L1 inhibitors in new combinations or using them in unexplored populations, one expert noted.

At last month's ASCO conference in Chicago, Pazdur was quoted in a Reuters article questioning the industry's current approach asking: "would we be better off spending those resources into looking at more novel drugs?" when discussing PD-1/PD-L1 inhibitors. He also noted that "the number of similar drugs in development at the same time is a first in the oncology field and latecomers to the PD-1 market will likely be relegated to 'niche' indications."

Bristol-Myers Squibb's (NYSE:BMJ) Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab) are examples of PD-1 inhibitors that have been approved for non-small-cell lung cancer (NSCLC) and melanoma. The former is additionally indicated for renal cell carcinoma and Hodgkin's lymphoma. AstraZeneca's (LON:AZN) durvalumab and Roche's (VTX:ROG)



Tecentriq (atezolizumab) are both PD-L1 inhibitors under investigation for the treatment of lung cancer. Tecentriq was recently approved in locally advanced or metastatic urothelial carcinoma.

The FDA did not respond in time for comment.

### Possible policy changes debated

Pazdur's comments will not signal any change in FDA policy such as accepting only innovative therapies beyond PD-1 and PD-L1 inhibitors or reviewing additional PD-1 therapies negatively, said Matthew Weinberg, CEO of consultancy The Weinberg Group, Washington, DC. The FDA has been aggressive in approving new oncology drugs in a timely way and this is unlikely to change, agreed Wayne Pines, president, Health Care, APCO Worldwide, Washington, DC. It's likely that Pazdur's intentions were just to encourage innovation in the space over policy change, said Dr David Lim, president and principal consultant, Regulatory Doctor, Roanoke, Virginia.

# The FDA may choose to become more critical on reviews and require larger studies for approval, or require longer term monitoring and stronger label warnings

The comments indicate Pazdur's personal views appealing for more breakthrough therapies with new targets rather than me-too/follow-on therapies, Weinberg and Pines said. The comments likely do not apply to all cancer immunotherapy, rather just the PD-1/PD-L1 inhibitors, Dr Grant Williams, president, Williams Cancer Drug Consulting, Philadelphia, Pennsylvania.

However, the FDA could potentially increase the bar for approval concerning PD-1/PD-L1 inhibitors as more is learned about their safety profiles, Lim explained. The FDA may choose to become more critical on reviews and require larger studies for approval, or require longer-term monitoring and stronger label warnings, he added.

Yet, the comments could still signal a change in FDA policy, said Nigel Smart, vice president, Smart Consulting Group, West Chester, Pennsylvania, with the agency giving greater priority to reviewing drugs with improved therapeutic value as opposed to me-too drugs.

Whilst the FDA won't change its overall policy, it's possible me-too PD-1/PD-L1 inhibitors may no longer qualify for the FDA's breakthrough designation or for accelerated approval, said Williams. Breakthrough designation allows more

access to agency advice and communication, and the accelerated approval path allows early approval based on surrogate endpoints, he noted. Both are available when there is an advantage over available therapy, he said. Thus, PD-1/PD-L1 inhibitors may have to go through the full development pathway of showing clinical benefit in a large randomized study before approval is granted, he said.

## Niche market options

Whilst Pazdur mentioned that latercomers would be relegated only to the "niche markets", one unnamed oncologist countered that this was unlikely. Companies developing novel PD-1/PD-L1 antibodies are often doing so for the purpose of new combinations, said the oncologist and Williams. Whilst a PD-1/PD-L1 inhibitor might offer nothing new in non-niche indications such as lung cancer, where there are approved PD-1 inhibitors, combining them with a novel therapy could provide patient value as it could boost response rates, explained the oncologist. This is especially important given the heterogeneity in response rates and the need for combinations to boost responses in certain individuals, he said.

For example, Tesaro (NASDAQ:TSRO) has its own PD-1 inhibitor yet to enter clinical trials, said the oncologist. However, the company intends to use it primarily in novel immunotherapy combinations, such as with anti-LAG-3 or anti-TIM-3 antibodies, as opposed to monotherapy trials in solid tumours, the oncologist explained. Other companies are looking at combining their own PD-1/PD-L1 inhibitors with other immunotherapy targets such as Ox40, GITR, 4-1BB amongst others, he added. This news service reported on 5 July that Pfizer has planned a Phase I trial for its PD-L1 inhibitor in combination with a 4-1BB agonist and an Ox40 agonist.

The unnamed oncologist noted that companies developing PD-1 inhibitors are now focusing on



niche areas that have not received much attention, such as mesothelioma, so breakthrough approval could still be attainable for PD-1/PD-L1 drugs in these cases. Williams agreed, noting breakthrough therapy is not dependent upon mechanism of action, but rather, upon the patient population being treated and whether an unmet medical need is being addressed. Even some of the bigger players entering the race later are targeting more niche populations with unmet needs, said the unnamed oncologist and Williams.

For example, Pfizer (NYSE:PFE) and Merck KGaA (ETR:MRK) are collaborating to develop their PD-L1 inhibitor, avelumab, in smaller patient populations such as Merkel cell carcinoma, said the unnamed oncologist. Some companies are selecting patients using genetic subgroups where PD-1/PD-L1 inhibitors may work best in unserved populations and leverage FDA opinion, said Williams. [W](#)



**Hamish McDougall**  
Reporter, London

Hamish has a BSc in Neuroscience from the University of Sussex and is primarily covering the neuroscience indications for BioPharm Insight. Prior to joining us he was assistant commissioning editor for a well-known collection of biomedical journals at Expert Reviews, including Expert Review of Gastroenterology & Hepatology, Expert Review of Clinical Pharmacology and Expert Review of Respiratory Medicine.



**Jennifer C. Smith-Parker**  
Journalist, London

Jennifer is an award-winning biopharmaceutical industry journalist. Prior to joining BioPharm Insight Jennifer was Associate News Editor at FDA Week, covering FDA regulatory policy for all FDA-regulated product areas. She also worked at The Monitor, where she covered health, environment and science issues and conducted a year-long project on indigent healthcare services. She was awarded the Texas Medical Association's Anson Jones journalism award for an article on breast cancer. Jennifer graduated from New York University with a Bachelor's with Honors in History and Journalism. Follow her on Twitter @JsmithParker



**Alaric DeArment**  
Reporter, New York

Alaric DeArment covers cancer drug development for BioPharm Insight. He served as associate editor of Drug Store News from 2008 to 2014, covering branded and generic drugs from development to distribution, retail and specialty pharmacy and regulatory affairs. In 2011-2012, he edited the book Contestation and Adaption: The Politics of National Identity in China. A native of Seattle, he graduated with honors with a bachelor degree in Journalism from Ball State University and also lived in China from 2001-2004. Follow Alaric on Twitter @AlaricD\_BPI

3 YEARS  
IN A ROW

Forbes 2015  
BEST BANKS  
IN AMERICA

BBCNbank.com

## IT'S YOUR COMMUNITY. LET'S BUILD IT AND GROW TOGETHER.

At BBCN, we know that hard work and a good partner is the way to grow within your community.

We invest in your potential.



Strength in Partnership -



# Kinexum

“Our goal is  
your success”



**Kinexum designs, guides and manages strategic and operational solutions to the regulatory, manufacturing, nonclinical and clinical development as well as commercial challenges necessary to bring healthcare products from proof of concept to commercialization.**

Our experts, whether as an individual consultant or as an integrated team, supplement the strengths of large and small organizations to reach high value milestones effectively and efficiently.

Kinexum specializes in crafting creative but sound and integrated solutions across scientific disciplines, therapeutic areas, product modalities and business stages.

[www.Kinexum.com](http://www.Kinexum.com)

We would be pleased to assist your organization, please contact us at [info@kinexum.com](mailto:info@kinexum.com) or visit our website for more information.

© 2016 Copyright Kinexum Services LLC. All right reserved



**The 1st**  
New Chemical Entity  
Insulin Sensitizer from Korea

**Duvie<sup>TM</sup> Tab.**

Lobeglitazone sulfate 0.5mg

*The Key of Insulin Sensitizer*  
*The Key of Insulin Resistance*

- Excellent Glycemic control & Safety profile <sup>1)</sup>
- Favorable Lipid Profile <sup>1)</sup>
- Improved Metabolic Syndrome <sup>1)</sup>



**SafeLan**

**Feel The Difference.**

The safest and most convenient method of blood sampling.

**SafeLan<sup>®</sup>**

**Specification**

- 26G - 0.45mm
- 30G - 0.30mm

**Features**

- Protective tip & Automatic detachment of the tip before use
- Minimizes risk of transmitting blood borne pathogens
- Prevents accidental needlestick injury associated with recapping



**30G**

Small blood sample  
for glucose monitoring



**26G**

Ideal for tough skin and  
larger blood sample

**SafeLan<sup>®</sup> - Pro**

**Specification**

- Penetration depth setting: 5 Levels of setting
- Penetration Range: 1.0~2.5mm
- Weight: 14.29g

**Features**

- Designed to prevent reuse of the lancet needle
- Rear window shows if lancet is ready for use
- Minimizes pain by accurate needling without vibration of the needle
- Customizable depth settings



**WMEDI  
TECH**

Online Purchases at [www.WMediTechUS.com](http://www.WMediTechUS.com)

# Democratizing Antibodies

“Will it be mammalian cells forever? Or is there an opportunity to get even better and to get to the next step change in productivity?”

Jorg Thommes, Biogen Inc.

## TOOLS & TECHNIQUES

## DEMOCRATIZING ANTIBODIES

By Michael Leviten, Senior Writer

With the goal of expanding access to antibody-based drugs worldwide, the [Bill & Melinda Gates Foundation](#) is turning to industry to innovate its methods of manufacturing the proteins. In the last two months, the organization signed deals with [Biogen Inc.](#) and [Just Biotherapeutics Inc.](#), fostering programs to reduce costs and increase yields that benefit both the for-profit and not-for-profit enterprises.

On Aug. 8, the Gates Foundation and Biogen announced a project to improve antibody production and manufacturing techniques, using eight undisclosed expression systems that include yeast, fungi and algae. The idea is to search for alternatives to Chinese hamster ovary (CHO) cells, which have served as the workhorse of antibody manufacturing for 25 years. Biogen will conduct the research over an 18-month period, and the results will be made publicly available.

Financial details were not disclosed but the organizations are contributing roughly equal amounts, according to Stephen Hadley, senior program officer for vaccine development at the Gates Foundation. Hadley said Biogen is also contributing an antibody to use as a benchmark and some of the analytics.

The partnership comes two weeks after the Gates Foundation invested \$8 million in a series A2 round for Just Biotherapeutics, a start-up focused on streamlining antibody production. A further \$6 million was invested by existing investors [Merck & Co. Inc.](#), Lilly Asia Ventures and [Arch Venture Partners](#). Last year, the foundation awarded the company \$24 million in grants over five years to develop low-cost HIV antibodies and technology platforms for low-cost biologics.

Despite the success of CHO cells for supporting antibody production, the yield has hit a ceiling after years of

optimization; however higher yields and more streamlined manufacturing are needed to reduce costs for emerging and third world markets.

But according to Tim Moore, EVP of technical operations at [Kite Pharma Inc.](#), since the 1990s when a platform based on CHO cells was established, there has been little motivation in industry to innovate or switch expression systems. Moore was previously SVP and global head of Pharmaceutical Technical Operations Biologics at [Roche's Genentech Inc.](#) unit.

“There were hardly any players in that space, so it made a lot of sense just to build upon [the early methods] and then come up with different ways to get higher titers,” he said.

Hadley told BioCentury that was the first challenge he faced when he joined the organization three years ago and was tasked with exploring mAbs for infectious diseases at production costs that could be practical in focus regions such as sub-Saharan Africa and South Asia.

“Most of the antibodies and biologics developed for the world marketplace enjoy extremely nice margins, so for cost of goods there has never been a pressure driver on the industry to figure out how to lower costs,” he said.

Hadley said there was little interest among most of the biotechs he spoke to about developing better methods. “Frankly, people are pretty set with their processes and installed capacity.”

However, the Gates Foundation's approach was to make “catalytic investments” that will get the field to move in a new direction, said Hadley, and to find industry partners that see a commercial benefit to improving the technology that complements rather than competes with the organization's

interests. “We don't have any alignments on products; this is all around technology. Their portfolio of products is different than our interests.”

Whereas the funding for Just Biotherapeutics supports lower-cost methodology for CHO-based manufacturing, the Biogen project is looking beyond CHO cells, and is using an open model that hopes to engage other companies that might see the upside of creating a next-generation, low-cost platform.

Jorg Thommes, SVP of technical development at Biogen, told BioCentury the field has reached an inflection point. “We're now at this point of saying ‘OK what's next?’ Will it be mammalian cells forever? Or is there an opportunity to get even better and to get to the next step change in productivity?” he said.

### WHOLESALE CHANGES

According to Thommes, the ongoing adherence to CHO cells has not been for want of trying to find alternatives. The problem has been that there's been no coherent or coordinated strategy to replace the cells.

“People have been trying out alternate expression systems for a long time,” he said. “And they've been executed sporadically with different focus. And there has never been a real head-to-head comparison of many alternate expression systems with the current high-productivity mammalian cells.”

Overall, the efficiency of antibody production from CHO cells has increased by a factor of nearly a thousand in the last 25 years, with common yields approaching 3-6 grams per liter of CHO cells, due largely to a greater understanding of CHO cell biology, said Thommes. “We've gotten much, much better at understanding what these cells need to grow and thrive so we can maximize their number in a reaction system and the time that we can keep them alive and happy.”

But those improvements also capped progress. “Mammalian cells make proteins that are very well tolerated by humans, and are fully functional. So there was no need to look outside of that mammalian cell box because we got so much better at it,” Thommes said.

However, the main drawback is the long growth cycle, he said. Mammalian cells are typically cultured for 10-14 days during a production run, compared with 2-3 days for yeast or bacteria. Microbes are used at large scale to produce biologics like insulin and human growth hormone, which are made in yeast and bacteria, respectively.

Thommes said that the main advances have been in the “upstream” part of antibody manufacturing, which involves protein production, where using lower-cost media and achieving higher titers has improved productivity and reduced costs. But the principal need is in the “downstream” part of the process which involves protein purification, where costs have remained stagnant.

“Most of the antibodies and biologics developed for the world marketplace enjoy extremely nice margins, so for cost of goods there has never been a pressure driver on the industry to figure out how to lower costs.”

Stephen Hadley, Bill & Melinda Gates Foundation

“Alternate expression systems with increased productivity will most likely present a different, possibly leaner, background to isolate antibodies from. This could open up intriguing opportunities for disruptive downstream processing technologies,” said Thommes. In particular, he thinks replacing traditional chromatography methods with other unit operations might be interesting, and the current focus on virus inactivation and removal steps for mammalian cell expression might be reduced with alternate hosts.

Hadley believes that the results of the Biogen project can seed bigger advances once opened up to the research community. “I think the trajectory would be similar to what happened with CHO. Eventually organizations, when they landed on CHO, they brought their own CHO cell lines and vector technologies into their own organizations, optimized them, and controlled the IP around that.”

### JUST SAYIN'

By contrast, the investment in Just Biotherapeutics is meant to help the start-up double down on CHO cells, using protein engineering and infrastructure improvements to reduce costs.

“It's the extreme opposite of the very large-scale stainless steel model that's been very successful, but there's a production cost floor that it's difficult to figure out how to break through,” said Hadley.

The company was started by a team of Amgen Inc. veterans, who aim to introduce changes throughout the process, from molecule design to facility layout, to lower costs tenfold and bring cheaper antibodies to developing markets.

“You have to look at it from everything from molecular design for manufacturability all the way through the plant and how well the plant is designed. So we can optimize in both directions.”

Jim Thomas, Just Biotherapeutics

“You have to look at it holistically. You have to look everything from molecular design for manufacturability all the way through the plant and how well the plant is designed. So we can optimize in both directions,” said Just CEO Jim Thomas.

Hadley said the Gates Foundation is solely interested in infectious disease antibodies in the project, which it wants to expand to third world nations, following the model of Synagis palivizumab, a humanized mAb against respiratory syncytial virus (RSV) from AstraZeneca plc’s MedImmune LLC unit.

For the HIV project, the target product profile calls for a subcutaneous product dosed quarterly. The aim is to use protein engineering to enable low-viscosity formulations at about 150 mg/mL, and modifications to the Fc region to extend the half-life.

Hadley said the Gates Foundation grant covers HIV antibodies from four different academic groups funded by the Collaboration for AIDS Vaccine Discovery (CAVD). The antibodies include eCD4-Ig from The Scripps Research Institute and 3BNC117 and 10-1074, which are in Phase I trials, from The Rockefeller University. █

COMPANIES AND INSTITUTIONS MENTIONED

- Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.
- AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
- Bill and Melinda Gates Foundation, Seattle, Wash.
- Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass.
- Genentech Inc., South San Francisco, Calif.
- Just Biotherapeutics Inc., Seattle, Wash.
- Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif.
- MedImmune LLC, Gaithersburg, Md.
- Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J.
- Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
- The Rockefeller University, New York, N.Y.
- The Scripps Research Institute, La Jolla, Calif.

REFERENCES

Li, V. "Manufacturing gateway." *BioCentury* (2016)

BIOCENTURY INC.

NEWSROOM

pressreleases@biocentury.com

SAN CARLOS, CA

+1 650-595-5333; Fax: +1 650-595-5589

CHICAGO

+1 312-755-0798; Fax: +1 650-595-5589

WASHINGTON, DC

+1 202-462-9582; Fax: +1 202-667-2922

UNITED KINGDOM

+44 (0)1865-512184; Fax: +1 650-595-5589

All contents Copyright © 2016 BioCentury Inc. ALL RIGHTS RESERVED. All use of BioCentury and its contents by current subscribers is governed by the BioCentury User Agreement and by all others is governed by the BioCentury Terms of Use, unless a written agreement to the contrary has been executed by BioCentury Inc. No part of BioCentury or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury Inc., which may be requested from Reprints/Permissions at www.biocentury.com.

**Trademarks:** BioCentury™; BCIQ™; The BioCentury 100™; Because Real Intelligence is Hard to Find™; and The Clear Route to ROI™ are trademarks of BioCentury Inc.

**Use of Images:** Certain Images used in BioCentury Inc.'s Publications, Video Content, Websites, Services, Notices and/or Marketing Materials are licensed from Getty Images (US), Inc. Any such image of a person or object so displayed is being used for illustrative purposes only and any such person or object depicted, if any, is merely a model. For more information see "Use of Images" found under the "About Us" tab on the Homepage at www.biocentury.com.

All information provided through BioCentury Inc.'s Publications, Video and Audio Content, and Websites is gathered from sources that BioCentury believes are reliable; however, BioCentury does not guarantee the accuracy, completeness, or timeliness of such information, makes no warranties regarding such information, and is not responsible for any investment, business, tax or legal decision made or action taken in reliance upon such information.

THE BIOCENTURY PUBLICATIONS PACKAGE

GET A FREE 4-WEEK TRIAL



BIOCENTURY

Weekly analysis, interpretation and commentary on biopharma industry corporate performance, product discovery and development, emerging companies and technology, public policy, regulatory events and innovation and financial markets

WEEK IN REVIEW

Weekly compendium of biopharma deals, clinical and regulatory events, and financial transactions

BIOCENTURY INNOVATIONS

Collection of in-depth articles identifying commercially promising translational science and assessments of the next steps required to develop the technology

BIOCENTURY EXTRA

Key industry news events published every business day for busy executives and investors

# NEW YORK

## Health Forum

6<sup>th</sup> Forum | September 27th, 2016  
The Yale Club of NYC

### "Korea Rise : New Strategies Transforming Korean Biopharma and Unparalleled Opportunities for Collaboration"

“ **Key Trends in US Biopharma/Medtech Investing**  
*5th Forum | March 31, 2016*

**Furthering Global Biopharma: Opportunities for Development with East Asia**  
*4th Forum | November 12, 2015*

**Future is Now: The Era of Mobile Health**  
*3rd Forum | May 21, 2015*

**The Pacific Connection: US- East Asia Pharma Collaboration**  
*2nd Forum | February 11, 2015*


**Forecasting Healthcare in 2015 & Trans-Cultural Healthcare**  
*1st Forum | December 18, 2014* ”

#### RSVP

🌐 [www.newyorkhealthforum.net](http://www.newyorkhealthforum.net)

✉ [info@wmedicalstrategy.org](mailto:info@wmedicalstrategy.org)

📞 (201) 402-1400



# Happy smile and hope after pain

D.K. Lee has related to It's A Wig that she will promote to cancer patients about the beauty classes and healing programs she attended. The beauty classes are held at Kyung Hee Medical Center and it is for cancer patients to help them feel more womanly during their hard times. She would like to thank all the people who gave her hope. "Thank you for giving me a second chance to live as a woman. With the hopes and gifts that I have received, it encourages me to work harder to volunteer my time for the people who are fighting against cancer."

Kyung Hee Medical Center patient  
D. K. Lee 🌸



D.K. Lee attending beauty classes while chemotherapy treatment



Cancer-free D.K. Lee

**mimosa™** its petals close quickly when touched.  
SENSITIVELY

With the honor of our wigs, her sensitive scalp has been revived. Our wigs help patients feel feminine, lively, and fashionable. We cater to your tender scalps with our high quality wigs. Mimosa hears your craving for the best fit.

**it's a wig!** supports cancer patients, foundations, clinics and hospitals by donating wigs. If you have questions or concerns about donation program *please contact*  
**Website: <http://www.itsawig.com>**  
**Phone: +1-201-621-4255**




# NY-ESO-1 therapy renewed enthusiasm underscored by new checkpoint inhibitors

NY-ESO-1 targeting immunotherapies are seeing renewed clinical development interest as the antigen is widely expressed in certain solid tumors and sarcomas, experts said. They noted recent checkpoint inhibitor approvals and modified T cell receptor (TCR) research underscore the enthusiasm, experts said.

Combinations with checkpoint inhibitors and other immune modulators have the potential to increase response rates seen with existing NY-ESO-1 directed vaccines, and TCR approaches offer newer strategies to exploit the NY-ESO-1 antigen over-expression in cancers. There is some caution on how well the approaches will pan out. Furthermore, experts expressed the need to target multiple additional antigens besides NY-ESO-1 to induce significant immune responses.

While Adaptimmune (NASDAQ:ADAP) and Immune Design (NASDAQ:IMDZ) are using a modified TCR approach with a Phase I/II NY-ESO TCR, and Phase I LV305 with CMB305, respectively, for multiple cancers, Celldex (NASDAQ:CLDX) is exploring a vaccine approach in different cancers with the Phase II CDX-1401, an NY-ESO-1-targeting vaccine. Early trials at academic centers like Memorial Sloan Kettering, New York and Roswell Park Cancer Institute are also underway.

Adaptimmune, Immune Design, Celldex did not respond to a request for comment.



## NY-ESO-1 antigen expression

NY-ESO-1 expression in normal tissues is relatively narrow and from an antigen standpoint, it is a wonderful antigen to start research with, said Dr Paul Sabbatini, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, New York.

The NY-ESO-1 antigen is widely expressed in synovial sarcoma (SS), myxoid round-cell liposarcoma (LPS), melanoma, ovarian cancer, glioblastoma (GBM) and other tumors, but it has the most potential in sarcomas and melanoma due to their being immunogenic in nature, experts said.



NY-ESO-1 is expressed highly in SS and myxoid round-cell LPS in about 60-70% of tumors, said Dr Sant Chawla, director, Sarcoma Oncology Center, Santa Monica, California. NY-ESO-1-targeting seem to especially benefit SS, and there have been remissions observed in these patients, said Dr Sebastian Bauer, professor of medicine, West German Cancer Center, Germany.

Among 24 patients in a Phase I study of Immune Design's LV305 in sarcomas, one had a partial response, and 13 had stable disease (SD), with a median progression-free survival (PFS) of 4.6 months, according to data presented at the ASCO annual meeting. Among 14 patients receiving CMB305, 10 had SD, with a median 5.5-month PFS.

NY-ESO-1 expression in ovarian cancer is said to be in the range of 42- 60%, said Sabbatini and Dr Oliver Dorigo, associate professor, obstetrics and gynecology, Stanford University Medical Center, Palo Alto, California. The NY-ESO-1 antigen has been of particular interest in ovarian cancer since as patients have had their ovaries removed, NY-ESO-1 expression in normal ovarian tissue is not a clinical issue, added Dorigo.

However, it's not necessarily the expression of the antigen, but also the tumor immunogenicity that's important, said Dr Brent Hanks, assistant professor of medicine, Duke University School of Medicine, Durham, North Carolina. Melanomas are just more responsive to immunotherapies than gastric or colon cancer, he added. NY-ESO-1 expression in melanoma can range from 25-50+%, depending on which research study is considered, he added.

Though melanomas do overexpress the antigen, it is unknown if that is enough to drive T cell responses, cautioned Dr Jason Luke, assistant professor of medicine, University of Chicago. Therapies that target NY-ESO-1 have been around for many years, he and Dr Anthony Olszanski, co-director, cutaneous oncology and melanoma, Fox Chase Cancer Center, Philadelphia agreed. Luke noted most researchers would find it unlikely that targeted NY-ESO-1 would be a particularly efficacious way to move forward. Previous studies have not shown any significant response rate in melanoma, Olszanski added. However, now with the introduction of PD-1 inhibitors, the hope is that a combination approach can capitalize on the antigen recognition and improve the efficacy of these therapies, he said.

# Ultimately, future research will focus on combination approach in the form of a vaccine with the checkpoint inhibitor

Across indications, it still needs to be explored if the ideal patient population would be one in remission with a lower disease burden, or those with active disease and a higher antigenic load, said Sabbatini.

## Promising combinations

NY-ESO-1 vaccinations have induced mild immune responses in a disease like ovarian cancer, but the question is always on how to enhance those responses across all tumor types, said Sabbatini. If the focus is on just one antigen and the induced immune response is not potent enough to generate T-cell responses to other antigens, then the tumor can simply down-regulate the expression or processing of those antigens, agreed Hanks and Dorigo. NY-ESO-1 expression in ovarian cancer is more heterogeneous and patchy than in others, and it might be necessary to target a second or third antigen or add another other antitumor treatment for a clinical response, Dorigo explained.

New co-stimulatory molecules and checkpoint inhibitors could modulate these immune responses, said Sabbatini. Ultimately, future research will focus on combination approach in the form of a vaccine with the checkpoint inhibitor, agreed Hanks. Other agents that have been designed to reverse immune suppression or reverse immune invasion by the cancer could be combined as well, he added. The next generation of therapies is looking at the addition of these immune molecules to elicit a robust immune response, said Sabbatini.

Immune Design is studying (NCT02609984) CMB305, a dendritic cell-targeting vector that expressed NY-ESO-1 and a NY-ESO-1 recombinant protein in combination with Roche's (VTX:ROG) Tecentriq (atezolizumab). An investigator sponsored Phase I trial (NCT02737787) at MSKCC will explore Bristol-Myers Squibb's

(NYSE:BMJ) Opdivo (nivolumab) in combination with a dual NY-ESO-1 and WT1-directed vaccine. Celldex is also evaluating CDX-1401 in a Phase I/II (NCT02413827) study in Stage III/IV melanoma patients in combination with its anti-CD27 antibody, varlilumab, and BMS' anti-CTLA4 antibody Yervoy (ipilimumab).

However, it is not clear if there's a role for NY-ESO-1-based vaccines and combination with checkpoint inhibitors have not proven to be particularly efficacious, differed Luke.



## TCRs or vaccines

The best way to target the antigen may depend on the host immune response, said Liao, adding that TCRs or vaccines could be potential strategies to use NY-ESO-1. For patients who are able to mount an active immune response, a vaccine may be optimal, while adoptive immunotherapy with engineered T cells may be preferable for those who cannot, she added.

By tailoring the antigen-targeting treatment to each patient, researchers can look at individual tumor presentation and customize T cell directed therapy, said Dorigo. One reason for the recent focus on TCRs is that chimeric antigen receptor T-cells (CAR-Ts) haven't been shown to be effective in solid tumors yet, said Dorigo, though they could be in the future. Adap-

timune is running multiple clinical trials where a patient's T cells are extracted and modified to identify NY-ESO-1 in ovarian cancer and certain sarcomas. However, with a TCR approach, the impact of induced myelosuppression on heavily pre-treated ovarian cancer patients is not yet known, said Dorigo.

Modifying T cells is a newer approach than vaccines, but vaccines have not been studied in combination with immune-modulating agents before, said Sabbatini. It is still too early to determine which approach would work best or how effective it would be, said Dorigo. [w](#)



### Alaric DeArment

Reporter, New York

Alaric DeArment covers cancer drug development for BioPharm Insight. He served as associate editor of Drug Store News from 2008 to 2014, covering branded and generic drugs from development to distribution, retail and specialty pharmacy and regulatory affairs. In 2011-2012, he edited the book *Contestation and Adaption: The Politics of National Identity in China*. A native of Seattle, he graduated with honors with a bachelor degree in journalism from Ball State University and also lived in China from 2001-2004. Follow Alaric on Twitter @AlaricD\_BPI



### Indrani Datta

Reporter, New York

Indrani Datta covers cancer drug development for BioPharm Insight. She holds a B.E. in Biochemical Engineering, a BS in Computer Science and a Masters in Journalism with a concentration in Health and Science Reporting from CUNY Graduate School of Journalism. Prior to joining BioPharm Insight, Indrani performed experimental lab work in a startup biotech company, worked as a bioinformatics statistician in academia and a LIMS (laboratory information management system) developer for various pharmaceutical companies. She also built interactives for The New York Times before founding a news web startup. Indrani has written about hospital finance and politics for various publications.



### Manasi Vaidya

Reporter, New York

Manasi Vaidya has a Masters degree in biotechnology. After a stint in a research lab, she spent two years as correspondent in India for BioSpectrum, a publication focused on the Asian biotechnology industry. She then moved to the United States to pursue a Masters degree in Science, Health and Environmental Reporting at New York University. Manasi has reported primarily on topics that combine health and policy, and her work has appeared in Nature Medicine, Nautilus and Scienceline. Her coverage at BioPharm Insight focuses on cancer.

# Synatura

Ivy leaf 30% ethanol ext. + Coptis Rhizoma butanol ext.

## Synatura is...

- No.1 antitussive & expectorant product in Korea
- Synergy effect by combination of natural products
- Best choice for inflammatory chronic bronchitis
- Proven safety and effect



 **Ahngook Pharmaceutical Co., Ltd**  
www.ahn-gook.com

Looking to start a  
clinical trial?

Have you seen what Australia has to offer?


- High quality clinical and pre-clinical research capabilities
- Political stability, safe & robust legal and regulatory system
- Quick start-up time of clinical trials
- Preferred location for incorporation in multi-national trials
- State-of-the-art medical research facilities and hospitals
- Strengths in pre-clinical and early clinical development phases
- Strong Government commitment and investment
- Favourable Australian Dollar Exchange Rates
- Access to 45% R&D Tax Credit\*

\*Contact LSQ to find out how to access the R&D Tax Credit

LSQ can help you get started.

Contact us now.

info@lsq.com.au  
+61 7 3331 3999  
www.lsq.com.au  
@LSQld



Life Sciences Queensland

# WHY “NEW STANDARD” READY-TO-USE




**INNOVATIONS**  
+

**ADVANTAGES**

**UK INJECTION KIT(FULL KIT)**



State of the art  
UK Injection Kit



**CONNECT  
TO VEIN  
DRIPPING  
SYSTEM**

- ✓ **CLOSED SYSTEM APPLICABLE FOR USP CHAPTER <797>**
- ✓ **REDUCE THE RISK OF MICROBIAL CONTAMINATION**
- ✓ **FASTER PREPARATION TIME WITH READY TO MIX SYSTEM**
- ✓ **REDUCE THE NEEDLE INJURY AND ANTIBIOTIC ALLERGY OF PRACTITIONER**
- ✓ **WIDE RANGE OF ANTIBIOTIC PRODUCT PORTFOLIO**
- ✓ **AND MORE INNOVATIONS & ADVANTAGES**

**UK Do-i Co.,Ltd.**

**UK Chemipharm Co.,Ltd.**

**BNCP Corporation**

[www.ukholdings.co.kr/index\\_en.html](http://www.ukholdings.co.kr/index_en.html)

# FOLLOW THE JOURNEY OF VIREAD

**COMPLETE RESPONSE RESULTS AT YEAR 1...**

**#1** Prescribed oral antiviral according to US prescription data for treatment of CHB<sup>1a</sup>

## AT YEAR 1

The primary endpoint—complete response\*—was evaluated in Studies 102 and 103<sup>2</sup>

## THROUGH YEAR 8

Resistance was evaluated as a secondary endpoint<sup>2,3</sup>

In Study 102 (HBeAg-, n=375) and Study 103 (HBeAg+, n=266), a combined total of 641 adult patients with chronic hepatitis B (CHB) and compensated liver disease who were primarily nucleoside treatment naïve entered a 48-week, randomized, double-blind, active-controlled treatment period comparing VIREAD 300 mg to adefovir dipivoxil 10 mg. Subjects who completed double-blind treatment at Week 48 were eligible to roll over with no interruption in treatment to open-label VIREAD. Of 641 patients enrolled in the initial trials, 412 (64%) completed 384 weeks of treatment.<sup>2</sup>

\*The primary endpoint in Studies 102 and 103 was complete response to treatment at 48 weeks as defined by HBV DNA <400 copies/mL (69 IU/mL) + histological response (Knodell necroinflammatory score improvement of ≥2 points without worsening in Knodell fibrosis score). Annual evaluation of resistance was a prespecified secondary endpoint. Cumulative VIREAD genotypic resistance was evaluated annually for up to 384 weeks in Studies 102, 103, 106, 108, and 121.<sup>2,3</sup>

**71%** of HBeAg- VIREAD patients vs **49%** of adefovir dipivoxil patients.<sup>2-4</sup>  
**67%** of HBeAg+ VIREAD patients vs **12%** of adefovir dipivoxil patients.<sup>2,3,5</sup>

## INDICATION AND USAGE

VIREAD® (tenofovir disoproxil fumarate) is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.

The following points should be considered when initiating therapy with VIREAD for the treatment of HBV infection:

- The indication in adults is based on data from treatment of subjects who were nucleoside-treatment-naïve and treatment-experienced with documented resistance to lamivudine. Subjects were adults with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver disease
- VIREAD was evaluated in a limited number of subjects with chronic hepatitis B and decompensated liver disease
- The numbers of subjects in clinical trials who had adefovir resistance-associated substitutions at baseline were too small to reach conclusions of efficacy

<sup>1a</sup>Healthcare Analytics Monthly data, August 2014-June 2015.

Please see Brief Summary of full Prescribing Information including **BOXED WARNING** on the following pages.

## IMPORTANT SAFETY INFORMATION

### BOXED WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS

- **Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, in combination with other antiretrovirals**
- **Severe acute exacerbations of hepatitis have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VIREAD. If appropriate, resumption of anti-hepatitis B therapy may be warranted**

**GILEAD IS COMMITTED TO THE EDUCATION AND TREATMENT OF CHRONIC HEPATITIS B.**

**viread**  
300mg tablets  
tenofovir disoproxil fumarate

# ...AT 8 YEARS: NO RESISTANCE WAS

Annual evaluation of resistance was a prespecified secondary endpoint for Studies 102 and 103 in HBeAg- and HBeAg+ chronic hepatitis B patients<sup>3</sup>; no evidence of resistance was found. Cumulative VIREAD genotypic resistance was evaluated annually for up to 384 weeks in Studies 102, 103, 106, 108, and 121.<sup>2,4,5</sup>

- In the nucleotide-naïve population from Studies 102 and 103, HBeAg+ subjects had a higher baseline viral load than HBeAg- subjects and a significantly higher proportion of the subjects remained viremic at their last time point on VIREAD monotherapy (15% vs 5%, respectively)<sup>2</sup>
- HBV isolates from these subjects who remained viremic showed treatment-emergent substitutions; however, no specific substitutions occurred at a sufficient frequency to be associated with resistance to VIREAD (genotypic and phenotypic analyses)<sup>2</sup>



Not an actual patient, but is representative of a real patient type. Models are used for illustrative purposes only.

## IMPORTANT SAFETY INFORMATION (cont'd)

### WARNINGS AND PRECAUTIONS

- **New onset or worsening renal impairment:** Cases of acute renal failure and Fanconi syndrome have been reported with the use of VIREAD. In all patients, assess estimated creatinine clearance (CrCl) prior to initiating and during therapy. In patients at risk for renal dysfunction, including those who previously experienced renal events while receiving adefovir dipivoxil, additionally monitor serum phosphorus, urine glucose, and urine protein. In patients with CrCl <50 mL/min, adjust dosing interval and closely monitor renal function. Avoid concurrent or recent use with a nephrotoxic agent. Cases of acute renal failure, some requiring hospitalization and renal replacement therapy, have been reported after initiation of high dose or multiple NSAIDs in HIV-infected patients with risk factors for renal dysfunction; consider alternatives to NSAIDs in these patients. Persistent or worsening bone pain, pain in extremities, fractures and/or muscular pain or weakness may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function
- **Coadministration with other products:**
  - Do not use in combination with other products containing tenofovir disoproxil fumarate
  - Do not administer in combination with adefovir dipivoxil
- **Patients coinfecting with HIV-1 and HBV:** Due to the risk of development of HIV-1 resistance, VIREAD should only be used in HIV-1 and HBV coinfecting patients as part of an appropriate antiretroviral combination regimen. HIV-1 antibody testing should be offered to all HBV-infected patients before initiating therapy with VIREAD
- **Bone effects:** Decreases in bone mineral density (BMD) and mineralization defects, including osteomalacia, have been seen in patients treated with VIREAD. Consider

assessment of BMD in adult and pediatric patients who have a history of pathologic bone fracture or other risk factors for bone loss. In a clinical trial conducted in pediatric subjects 12 to <18 years of age with chronic hepatitis B, total body BMD gain was less in VIREAD-treated subjects as compared to the control group. In patients at risk of renal dysfunction who present with persistent or worsening bone or muscle symptoms, hypophosphatemia and osteomalacia secondary to proximal renal tubulopathy should be considered

### ADVERSE REACTIONS

- **In HBV-infected subjects with compensated liver disease:** Most common adverse reaction (all grades) was nausea (9%). Other treatment-emergent adverse reactions reported in >5% of patients treated with VIREAD included: abdominal pain, diarrhea, headache, dizziness, fatigue, nasopharyngitis, back pain, and skin rash
- **In HBV-infected subjects with decompensated liver disease:** Most common adverse reactions (all grades) reported in ≥10% of patients treated with VIREAD were abdominal pain (22%), nausea (20%), insomnia (18%), pruritus (16%), vomiting (13%), dizziness (13%), and pyrexia (11%)

### DRUG INTERACTIONS

- **Didanosine:** Coadministration increases didanosine concentrations. Use with caution and monitor for evidence of didanosine toxicity (e.g., pancreatitis, neuropathy). Didanosine should be discontinued in patients who develop didanosine-associated adverse reactions. In patients weighing >60 kg, the didanosine dose should be reduced to 250 mg once daily when it is coadministered with VIREAD and in patients weighing <60kg, the didanosine dose should be reduced to 200 mg once daily when coadministered with VIREAD

# DETECTED AT YEAR 1 THROUGH YEAR 8

# 0%

**NO HBV RESISTANCE DEVELOPED YEAR 1 through YEAR 8 in clinical trials (Studies 102 and 103)<sup>2,3\*</sup>**

\*Data for Years 2 through 8 are from the open-label phase.<sup>6</sup>

- There was a 64% (412/641) retention rate at Year 8: 266/426 patients given VIREAD→VIREAD; 146/215 patients given adefovir dipivoxil→VIREAD<sup>2,6</sup>

## IMPORTANT SAFETY INFORMATION (cont'd)

### DRUG INTERACTIONS (cont'd)

- **HIV-1 protease inhibitors:** Coadministration decreases atazanavir concentrations and increases tenofovir concentrations; use atazanavir given with ritonavir. Coadministration of VIREAD with atazanavir and ritonavir, darunavir and ritonavir, or lopinavir/ritonavir increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity
- **Drugs affecting renal function:** Coadministration of VIREAD with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir

### DOSAGE AND ADMINISTRATION

- Recommended dose, in adults and pediatric patients ≥12 years of age (≥35 kg), for the treatment of chronic hepatitis B: one 300 mg tablet, once daily, taken orally, without regard to food
- In the treatment of chronic hepatitis B, the optimal duration of treatment is unknown
- Safety and efficacy in pediatric patients <12 years of age or weighing <35kg with chronic hepatitis B have not been established
- The dosing interval of VIREAD should be adjusted (using recommendations in the table below) and renal function closely monitored in patients with baseline creatinine clearance <50 mL/min

### DOSAGE ADJUSTMENT FOR PATIENTS WITH ALTERED CREATININE CLEARANCE

	Creatinine clearance (mL/min) <sup>a</sup>			Hemodialysis patients
	≥50	30-49	10-29	
Recommended 300 mg dosing interval	Every 24 hours	Every 48 hours	Every 72 to 96 hours	Every 7 days or after a total of approximately 12 hours of dialysis <sup>b</sup>

<sup>a</sup>Calculated using ideal (lean) body weight.

<sup>b</sup>Generally once weekly assuming three hemodialysis sessions a week of approximately 4 hours duration. VIREAD should be administered following completion of dialysis.

- The pharmacokinetics of tenofovir have not been evaluated in non-hemodialysis patients with creatinine clearance <10 mL/min; therefore, no dosing recommendation is available for these patients
- No dose adjustment is necessary for patients with mild renal impairment (creatinine clearance 50-80 mL/min). Routine monitoring of estimated creatinine clearance, serum phosphorus, urine glucose, and urine protein should be performed in these patients
- No data are available to make dose recommendations in pediatric patients with renal impairment

Please see Brief Summary of full Prescribing Information including **BOXED WARNING** on the following pages.

**References:** 1. Data on file, Gilead Sciences, Inc. Healthcare Analytics. 2. VIREAD [package insert]. Foster City, CA: Gilead Sciences, Inc.; May 2015. 3. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med.* 2008;359(23):2442-2455. 4. Data on file, Gilead Sciences, Inc. Study 102 CSR. 5. Data on file, Gilead Sciences, Inc. Study 103 CSR. 6. Marcellin P, Gane EJ, Flisiak R, et al. Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials [AASLD abstract 229]. *Hepatology.* 2014;60(4)(suppl):313A-314A.

For more information, visit [www.viread.com/hcp](http://www.viread.com/hcp)

**viread**<sup>®</sup>  
300mg tablets  
tenofovir disoproxil fumarate





# HOLY NAME MEDICAL CENTER

IT'S NOT JUST OUR JOB TO SERVE EVERY MEMBER OF OUR COMMUNITY.  
IT'S OUR MISSION.

**1,000 PHYSICIANS**  
**LEADING-EDGE MEDICAL & SURGICAL SPECIALTIES**  
**CULTURALLY SENSITIVE, COMPASSIONATE CARE**

EMERGENCY CARE CENTER \* REGIONAL CANCER CENTER \* CARDIAC AND STROKE CARE  
MINIMALLY INVASIVE SURGERY \* BREAST CENTER \* ASIAN LIVER CENTER  
ASIAN DIABETES CENTER \* DIALYSIS CENTER \* INPATIENT SERVICES  
CENTER FOR SLEEP MEDICINE \* CENTER FOR PHYSICAL REHABILITATION \* ORTHOPEDIC CENTER  
MULTIPLE SCLEROSIS CENTER \* RADIOLOGY SERVICES \* HOME HEALTH CARE  
HOSPICE AND PALLIATIVE CARE \* MATERNAL/CHILD HEALTH SERVICES \* PAIN MANAGEMENT SERVICES  
KOREAN MEDICAL PROGRAM \* CHINESE MEDICAL PROGRAM \* FILIPINO MEDICAL PROGRAM

Holy Name Medical Center   
Asian Health Services

718 Teaneck Road, Teaneck, NJ 07666 | [www.holyname.org](http://www.holyname.org) | For Asian Health Services, call 201-833-3399



THIS  
IS  
WHO  
WE  
ARE

## For Evidence-Based Laboratory Medicine

### Seoul Clinical Laboratories (SCL)

was established in 1983 as Korea's first specialized clinical and pathology reference laboratories.

Since then, SCL has taken a leading role in the field of both clinical diagnostic and specialized analytic techniques, and has continuously pursued 3 core values, Service, Quality and Research.

At present, SCL with 24-hour operational system provides full services for about 4,000 clinics and hospitals nationwide and is also constructing a global network with Mayo Clinics, Quest Diagnostics, Inc., USA, Mitsubishi Chemical Medience Co., Japan, and Dian Diagnostics, in China.

### Diagnostic Innovations

*We are passionate about developing innovative, ground breaking tests, products and tools to enhance patient care, provide value to our clients, and transform information into knowledge and insights.*



Expertise  
Across Multiple  
Disciplines



 Quality, Service, Research  
Seoul Medical Science Institute  
**Seoul Clinical Laboratories**

12, Jangmun-ro 6-gil, Yongsan-gu, Seoul, Korea  
Tel : +82-2-790-6500 | Call Center : 82-2-330-2001~3  
Website : <http://www.scllab.co.kr>

# Conference Alerts

## North America

### Natural Products Expo East

September 21-24, 2016/ Baltimore, MD, USA

**Website:** <http://www.expoeast.com/ee16/public/enter.aspx>  
Contact: tradeshows@newhope.com

Attended by 24,000 industry professionals and featuring thousands of exhibits, Natural Products Expo East is the largest natural, organic, and healthy products trade show on the East Coast. With the newest and best-selling products and branded ingredients available, this show features the best in organics, offers an extensive retailer training program and provides an advocacy platform through a strategic partnership with Natural Products Association East. Natural Products Expo East is ranked as one of the top 200 tradeshows in the US.

### 6th New York Health Forum

September 27, 2016/ New York, New York, USA

**Website:** [www.newyorkhealthforum.net](http://www.newyorkhealthforum.net)  
Contact: (201)402-1400

6th New York Health Forum's title is "Korea Rise: New Strategies Transforming Korean Biopharma and Unparalleled Opportunities for Collaboration." This forum will provide the setting for stimulating and informative discussions on the investment trends, landscapes, risks, and more. Investors, biopharma and medtech representatives, and healthcare professionals will all come together to connect, learn, and share.

### 15th Annual Trans-Pacific Health Sciences Dialogue

September 21-24, 2016/ Baltimore, MD, USA

**Website:** <http://transpacifichsd.com/>  
Contact: conferences@demy-colton.com

The 15th Annual Trans-Pacific Health Sciences Dialogue is a meeting for biopharmaceutical industry executives and business development executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America.

### SupplySide West

Oct 4-8, 2016/ Las Vegas, Nevada, USA

**Website:** <http://west.supplysideshow.com/>  
Contact: SupplySideWest@experient-inc.com

For 20 years, CPG manufacturers, marketers and formulators have relied on SupplySide West when searching for their next innovative ingredient. SupplySide West will have thousand exhibitors and 120 hours of education programming bringing together companies in the global dietary supplement, functional food and beverage, personal care, and sports nutrition industries.

### The 58th American Society of Hematology (ASH) Annual Meeting & Exposition

December 3-6, 2016/San Diego, California, USA

**Website:** <http://www.hematology.org/Annual-Meeting/>  
Contact: (888)273-5704

The American Society of Hematology (ASH) Annual Meeting is the world's premier event in malignant and non-malignant hematology. The meeting provides an invaluable educational experience and an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. This meeting will allow networking with top minds in the field, as well as a global community of more than 20,000 hematology professionals from every subspecialty.

### 28th Annual National Forum on Quality Improvement in Health Care

December 4-7, 2016/Orlando, Florida, USA

**Website:** <http://www.ihl.org/education/Conferences/Forum2016/Pages/default.aspx>  
Contact: info@ihl.org

IHI's Annual National Forum on Quality Improvement in Health Care is more than a chance to network with nearly 6,000 health care professionals and gain actionable ideas for your organization. It's also an opportunity to play a part in effecting real change in health care quality and safety.

### Keystone Symposia: Cellular Stress Responses and Infectious Agents

December 4-8, 2016/Santa Fe, New Mexico, USA

**Website:** <http://www.keystonesymposia.org/17S4>  
Contact: info@keystonesymposia.org

The conference will bring together cell biologists studying various cellular stress responses and researchers interested in how various infectious agents activate and manipulate host cellular stress responses. This conference focuses on the study of interactions between infectious agents and these pathways providing new insights about cellular stress responses and identifying new targets for the development of novel therapies for the treatment of infectious diseases.

### The 2017 HIMSS Annual Conference & Exhibition

February 19-23, 2017/Orlando, Florida, USA

**Website:** <http://www.himssconference.org>  
Contact: himss@compusystems.com

The 2017 HIMSS Annual Conference & Exhibition brings together 40,000+ health IT professionals, clinicians, executives and vendors from around the world. Exceptional education, world-class speakers, cutting-edge health IT products and powerful networking are hallmarks of this industry-leading conference. More than 300 education programs feature keynotes, thought leader sessions, roundtable discussions and workshops, plus a full day of preconference symposia.

### 17th Annual Minimally Invasive Surgery Symposium 2017

February 28-March 3, 2017/Las Vegas, Nevada, USA

**Website:** <http://www.miss-cme.org/site/Default.aspx>  
Contact: klally@hqtrs.com

The 17th Annual Minimally Invasive Surgery Symposium (MISS) will offer compelling lectures, surgical video presentations, and lively discussions and debates by world-renowned experts on advanced laparoscopic techniques for managing metabolic disorders, hernia, foregut and diseases of the colon.



## Europe

### CPhi Worldwide

October 4-6, 2016/ Barcelona, Spain

**Website:** <http://www.cphi.com/europe>  
Contact: customerservice@ubm.com

CPhi Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, hosts more than 36,000 visiting pharma professionals over three days. 2,500+ exhibitors from 150+ countries gather at the event to network and take advantage of more than 100 free industry seminars. It will be a great opportunity to establish new business relationships, meet with global partners and stay updated on the latest industry trends. The exhibition showcases cover the whole spectrum of pharmaceutical manufacturing and ingredients sourcing, offering products and services that cover the entire supply chain.

### 17th International Conference on Lung Cancer

December 4-7, 2016/Vienna, Austria

**Website:** <http://wclc2016.iaslc.org>  
Contact: wclc2016-registration@icsevents.com

The 17th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC) focuses on the science of lung cancer, which is advancing very rapidly. The Conference motto "WCLC 2016 Together against Lung Cancer" captures the collaborative spirit of the Conference which will be a scientific and educational event covering three major topics: Active Prevention, Accurate Diagnosis, and Advanced Care. Medical doctors, scientists, nurses, health professionals, government officials, partners from the industry, health advocacy groups and patients will come together in order to obtain and exchange information.

### 8th European Multidisciplinary Colorectal Cancer Congress

December 11-13, 2016, Amsterdam, Netherlands

**Website:** [http://www.emccc2016.org/en/Home\\_10\\_6\\_12.html](http://www.emccc2016.org/en/Home_10_6_12.html)  
Contact: info@congresscare.com

The European Multidisciplinary Colorectal Cancer Congress (EMCCC) is the European conference that truly provides a platform for in-depth multidisciplinary interaction among the various research areas. The conference will have separate workshops on surgery, medical oncology, radiotherapy, pathology, imaging, gastroenterology, and genetics, but all other sessions are plenary in order to have optimal interaction between all disciplines.

### 31st International Papillomavirus Conference

February 28-March 4, 2017, Cape Town, South Africa

**Website:** <http://hvp2017.org>  
Contact: reg\_hpv17@kenes.com

Through workshops, invited lectures, and oral and poster sessions presenting the latest research results, the conference will cover papillomavirus (PV)-related topics from basic science to global health impact. The conference themes will include the epidemiology and molecular biology of PVs; animal models for the study of papillomaviral disease; impact of the microbiome on HPV; basic immunology and pathogenesis of PVs; therapeutic and prophylactic vaccines; prevention of cervical cancer and other PV-associated diseases, and promotion of the spread of the scientific knowledge to benefit the whole community.



### 2017 Pharma CI Europe Conference & Exhibition

February 21-22, 2017, Prague, Czech Republic

**Website:** <http://europe.pharmaciconference.com/>  
Contact: info@pharmaciconference.com

This is the event featuring a world-class line up of speakers and panelists offering their unique insights and expertise on the topics you care about the most. The Pharma CI Conference & Exhibition is the industry's gold standard for senior level pharma, biotech, and device professionals seeking the latest news and the rare chance to network with all the industry's luminaries.

### The 13th International Conference on Alzheimer's & Parkinson's Diseases

March 29-April 2, 2017/ Vienna, Austria

**Website:** <http://adpd2017.kenes.com>  
Contact: reg\_adpd17@kenes.com

The series of Alzheimer's and Parkinson's Diseases Conferences attract international medical and scientific professionals worldwide. The Conference is at the forefront of unraveling the mechanisms and improving the treatment of Alzheimer's, Parkinson's and other related neurodegenerative diseases. AD/PDTM Conferences uniquely combine distinct neurodegenerative diseases in one setting and examine their similarities and differences; a strong focus is mechanisms of disease, prevention and therapy.

## Asia

### 7th Emirates Otorhinolaryngology Audiology and Communication Disorders Congress

January 18-20, 2017/Dubai, United Arab Emirates

**Website:** <http://www.emiratesrhinologyandotology.ae/>  
Contact: eroc@mic-group.com

The 2017 congress will provide a platform to share experiences and discuss breakthroughs in various specialist fields, a necessary prerequisite to successfully assess and expand practices. The congress includes keynote lectures, round table discussions, instructional courses, video sessions, and abstract sessions covering a wide array of topics and introduces latest technologies and techniques in the field. There will also be several live surgical pre-congress workshops on state of the art anatomical specimens.

### 12th Congress of Asia & Oceania Thyroid Association 2017

March 16-19, 2017/Busan, South Korea

**Website:** <http://www.aota2017.com>  
Contact: office@aota2017.com

The congress will feature the latest advances in thyroidology as well as an update on the day to day practice of clinical thyroidology by renowned experts from the region. Since it had been established in 1975, Asia & Oceania Thyroid Association (AOTA) has grown rapidly and now it is one of the leading medical societies in Asia. At this congress, a number of thyroid experts from different Asian countries will bring together to exchange their scientific knowledge and build a strong networking with each other. These experts will highlight the peculiar nature of thyroid diseases in our region.



# GREEN ALLEY

ECO-LUXE BEAUTY STORE

isoi

VANT 36.5

◁ | < | ⊞ | ⊙  
KICHO



Now available at Whole Foods Market  
COLUMBUS CIRCLE, TRIBECA, WILLIAMSBURG  
PORT CHESTER, EDGEWATER, PARAMUS, SPRING LAKE WALL and more

Online store \_ [www.greenalleyshop.com](http://www.greenalleyshop.com)

## BIOPHARM INSIGHT

THE MOST COMPREHENSIVE LIFE SCIENCE MARKET INTELLIGENCE AND ANALYTICS SOLUTION, FEATURING EXCLUSIVE FORWARD LOOKING NEWS AND THOUSANDS OF HEALTHCARE DATA POINTS, AGGREGATED INTO ONE CENTRALIZED SOURCE.

get ahead at [www.biopharminsight.com](http://www.biopharminsight.com)

GREEN ALLEY

210(B) Sylvan Avenue Englewood Cliffs NJ 07632

## August~September



# Brief View of the Latest Healthcare Industry

August ~ September 2016

## 1. Pfizer to Buy Cancer Drug Maker in \$14 Billion Deal

Pfizer has acquired Medivation, which makes the big-selling drug Xtandi to treat prostate cancer, with a \$14 billion agreement, representing \$81.50 a share in cash. Pfizer, just as all the other pharmaceutical companies, is making a big push into oncology. The main big reason is that cancer drugs can sell for well over \$100,000 a year and so far have been more resistant to cost-cutting efforts by insurers than drugs for some other diseases. Xtandi has generated \$2.2 billion in global sales in the last four quarters and analysts see sales eventually reaching \$4 billion or more annually. Ian Read, chairman and chief executive of Pfizer, expects that proposed acquisition of Medivation will immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer.

<http://www.nytimes.com/2016/08/23/business/dealbook/medivation-pfizer-14-billion-deal>.

[html?rref=collection%2Ftimestopic%252FPfizerInc.&action=click&contentCollection=business&region=stream&module=stream\\_unit&version=latest&contentPlacement=5&pgtype=collection&mtref=www.nytimes.com&\\_r=0](http://www.nytimes.com/2016/08/23/business/dealbook/medivation-pfizer-14-billion-deal)

## 2. Why a Chinese Billionaire is Now the Biggest Investor in CHS

Turnover among top shareholders of distressed Community Health Systems has happened so dramatically over the past eight months that management could be excused if they need an introduction to the newcomers. The new largest shareholder of CHS is Tianquiao Chen, a Chinese billionaire, and he has announced that he had accumulated about 11.4 million shares of CHS, or 10% of common shares. During the time Chen and Wellington, second largest shareholder, were buying big into CHS this year, the company's stock was trading for less than \$20 a share whereas it was traded for \$60 a share a year ago. Neither Chen nor Wellington likely intend to be activist investors and demand board seats to foist operational changes on management.

<http://www.modernhealthcare.com/article/20160820/MAGAZINE/308209967/why-a-chinese-billionaire-is-now-the-biggest-investor-in-chs>

[biggest-investor-in-chs](http://www.modernhealthcare.com/article/20160820/MAGAZINE/308209967/why-a-chinese-billionaire-is-now-the-biggest-investor-in-chs)

## 3. U.S. Funding for Fighting Zika Virus is Nearly Spent, C.D.C. Says

The director of the Centers for Disease Control and Prevention warned that federal funds to fight the Zika virus were nearly exhausted, and that if Congress did not replenish them soon, there would be no money to fight a new outbreak. The C.D.C. had spent \$194 million of the \$222 million it was allocated to fight the virus. The issue of funding is urgent because the Gulf Coast, where the Zika mosquito mostly lives, is only about halfway through peak mosquito season and the chances that the virus could start circulating in Houston or New Orleans are relatively high. There is currently a record of 16 infants born in the US with Zika-related microcephaly.

<http://www.nytimes.com/2016/08/31/health/us-funding-for-fighting-zika-virus-is-nearly-spent-cdc-says>.

[html?rref=collection%2Fsectioncollection%2Fhealth&action=click&contentCollection=health&region=stream&module=stream\\_unit&version=latest&contentPlacement=39&pgtype=sectionfront](http://www.nytimes.com/2016/08/31/health/us-funding-for-fighting-zika-virus-is-nearly-spent-cdc-says)

## 4. HCA Pouring \$2.7 Billion into Hub Hospitals and Markets

HCA Holdings plans to spend \$2.7 billion this year to expand patient access in its hub markets. HCA, the nation's largest investor-owned hospital chain, is developing more than a dozen free-standing emergency rooms in its markets through 2017 to go along with the 57 already open. HCA is also adding ambulatory surgery centers, urgent-care centers, diagnostic centers, and new hospital wings to provide convenience and the right setting for the severity of illnesses and injuries. Healthcare demand has been up 4% and more across the country. But that is likely to taper to a more traditional 2% rate and HCA wants to be ready to capture those patients at any point in the continuum by having the facilities in place when patients come.

<http://www.modernhealthcare.com/article/20160908/NEWS/160909906/hca-pouring-2-7-billion-into-hub-hospitals-and-markets>

## 5. EpiPen Price Rises Could Mean More Riches for Mylan Executives

Mylan, the pharmaceutical giant, has been vilified for price increases on its EpiPen allergy treatment. Although Nina Devlin, a spokesperson stated that Mylan's big price increases were not intended to help propel its performance toward the earnings and stock price targets, Brian Foley, an independent compensation consultant argued it is impossible to separate the company's business decisions from its pay practice. Under the grant, Mylan executives will be rewarded if the company's earnings and stock price meet certain goals by the end of 2018. Given that EpiPen accounted for \$1 billion of Mylan's \$9.4 billion in revenue in its most recent year, the allergy treatment's price increases seem integral to meeting those targets and generating a big payday.

<http://www.nytimes.com/2016/09/04/business/at-mylan-lets-pretend-is-more-than-a-game>.

[html?rref=collection%2Fsectioncollection%2Fhealth&action=click&contentCollection=health&region=stream&module=stream\\_unit&version=latest&contentPlacement=28&pgtype=sectionfront](http://www.nytimes.com/2016/09/04/business/at-mylan-lets-pretend-is-more-than-a-game)

## 6. Obamacare Premiums Set to Rise, Even for Savvy Shoppers

In the last few years, even though premiums in the Affordable Care Act's health insurance marketplaces were rising, most customers could avoid a big price rise by shopping for a cheaper plan. Next year, according to a preliminary analysis, that is going to be a lot harder. There is expected to be an average premium increase of 11%. The plans that were least expensive this year in the popular "silver" category are no longer price leaders in most markets. People who want to stay in their current plan could face much larger increases.

<http://www.nytimes.com/2016/09/01/upshot/obamacare-premiums-set-to-rise-even-for-savvy-shoppers>.

[html?rref=collection%2Fsectioncollection%2Fhealth&action=click&contentCollection=health&region=stream&module=stream\\_unit&version=latest&contentPlacement=32&pgtype=sectionfront](http://www.nytimes.com/2016/09/01/upshot/obamacare-premiums-set-to-rise-even-for-savvy-shoppers)

## 7. A Push to Lower Drug Prices That Hit Insurers and Employers the Hardest

Insurers and employers say that a big financial shock has come from a largely overlooked source: expensive anti-inflammatory medications like Humira and Enbrel, drugs taken by millions of people for conditions like rheumatoid arthritis. In recent years, the prices of these medications have doubled, making them the costliest drug class in the country. Express Scripts, the nation's largest drug benefits manager, changed its recommendations to insurers and employers saying they should cover fewer drugs for many inflammatory conditions. The idea is that the new limits will force drug companies to lower their prices, saving insurers and employers money.

<http://www.nytimes.com/2016/09/09/business/express-scripts-urges-narrower-coverage-of-anti-inflammatory-drugs>.

[html?rref=collection%2Fsectioncollection%2Fhealth&action=click&contentCollection=health&region=stream&module=stream\\_unit&version=latest&contentPlacement=6&pgtype=sectionfront](http://www.nytimes.com/2016/09/09/business/express-scripts-urges-narrower-coverage-of-anti-inflammatory-drugs)

**8. Pfizer Snaps Up Gene Therapy Group Bamboo for \$645m**

Pfizer has snapped up the remaining stake in privately-held, US gene therapy group Bamboo Therapeutics in a deal that could be worth as much \$645 million. The US drug giant already owned around 22% of the firm's fully diluted equity, and has now acquired the remainder for an upfront payment of \$150 million. Under the deal, Bamboo's selling shareholders will also be eligible for potential milestone payments of up to \$495 million contingent upon the progression of key assets through development, regulatory approval and commercialization. The move significantly ramps up Pfizer's expertise in gene therapy.

[http://www.pharmatimes.com/news/pfizer\\_snaps\\_up\\_gene\\_therapy\\_group\\_bamboo\\_for\\_\\$645m\\_1087970](http://www.pharmatimes.com/news/pfizer_snaps_up_gene_therapy_group_bamboo_for_$645m_1087970)

**9. Pharma Industry Should Self-Police Drug Prices, Allergan CEO Says**

Recently, a pharmaceutical company, which makes products such as Botox, pledged to limit annual increases on prescription drugs and Brent Saunders, Allergan CEO believes others can and should do the same. He says that government intervention isn't the answer to keeping drug prices in line. Saunders announced that Allergan would self-police their prices and raise prices no more than once a year. Allergan is getting a positive feedback from the drug industry.

<http://www.cnbc.com/2016/09/08/pharma-industry-should-self-police-drug-prices-allergan-ceo-says.html>

**10. Why You've Probably Never Heard of the Mysterious Scientist Behind One of the Greatest Advances in Neuroscience**

The new lab technique, called optogenetics, is one of the biggest breakthroughs in neuroscience in decades and it has the potential to cure blindness, treat Parkinson's disease, and relieve chronic pain. Two American inventors, Karl Deisseroth at Stanford University and Ed Boyden at the MIT have collected tens of millions in grants and won millions in prize money in recent years for their breakthrough invention. However, it turns out that it may be Zhuo-Hua Pan who invented optogenetics first. Pan is a vision scientist at Wayne State University who was driven by a desire to cure blindness and came up with the germ of the idea of optogenetics in the early 2000s. Boyden et al. and Pan worked on channelrhodopsin during similar time frame. However, Pan wasn't able to receive much attention only because the editor at Nature Neuroscience published Boyden's paper first.

<http://www.businessinsider.com/zhuo-hua-pan-optogenetics-2016-9?from=singlemessage&isappinstalled=0>

**11. Health Care Providers Scramble to Meet New Disaster Readiness Rule**

An estimated 72,315 American health care providers and suppliers will have a little over a year to meet federal disaster preparedness requirements completed early September by the Centers for Medicare and Medicaid Services. The new rule is aimed at preventing the severe breakdown in patient care that follows natural disasters while also strengthening the ability to provide services during other types of emergencies, such as pandemics and terrorist attacks. The rule is unusual in that it has provisions for 17 different provider types, including outpatient surgery site, physical therapy offices and home health agencies. While the vast majority of organizations have had to adhere to at least some emergency preparedness requirements for accreditation, others were not subject to any and it is expected to have a big impact on those facilities.

<http://www.nytimes.com/2016/09/10/us/medicare-requirements-disaster-readiness.html>

**12. Don't Worry about Orphan Drug Costs, Study Says. The Years of Fast Growth are Over**

Researchers at IMS Health and Celgene state that a years-long upswell in orphan drug spending should slow down. The IMS Health and Celgene authors found that – when limited to rare disease indications – orphan drug spending grew to \$30 billion in 2013 from \$15 billion in 2007. However, the authors expect that growth to slow down for the 2014-2018 period.

<http://www.fiercepharma.com/pharma/rising-orphan-drug-costs-aren-t-a-cause-for-concern-study-contents>

**13. St. Jude Sues Short-Seller Over Heart Device Allegations**

St. Jude Medical Inc sued short-selling firm Muddy Waters and cybersecurity company MedSec Holdings Ltd, saying they intentionally disseminated false information about its heart devices to manipulate its stock. Muddy waters, run by Carson Block, said in late August that St. Jude's pacemakers and defibrillators, which are used to regulate heart rhythm and treat cardiac arrest, had cybersecurity flaws that enabled them to be hacked and manipulated, with potentially fatal consequences. These accusations based on research from start-up cybersecurity company MedSec, knocked St. Jude's shares back 10% on Aug.25. In the lawsuit, St. Jude stated that Block's statements were defamatory and false.

<http://www.reuters.com/article/us-st-jude-medical-cyber-idUSKCN11D1FR>

**14. Congressman Wants a Hearing on Cosmetics Safety**

Politicians are putting pressure on the FDA to review and potentially revise existing regulations that govern the cosmetic industry to make sure products are safe. Rep. Frank Pallone Jr noted that there haven't been substantial changes to policies regarding cosmetics since 1938, when the FDA was first charged with overseeing cosmetic safety. He says that the committee with jurisdiction over cosmetic regulation should examine the existing framework and determine that improvements are necessary. With the cosmetic industry raking in hundreds of billions of dollars per year, projected to reach \$675 billion in revenue by 2020, it's an important time for a review to ensure consumer safety.

<https://www.yahoo.com/beauty/congressman-wants-a-hearing-on-cosmetics-safety-232444488.html>

**15. FDA Warns Ovarian Cancer Tests Not Reliable**

The U.S. Food and Drug Administration warned that screening tests for ovarian cancer are not reliable and should not be used. Despite extensive research and published studies, currently there are no accurate screening tests for ovarian cancer. However, numbers of companies have marketed tests that claim to screen for and detect ovarian cancer. But these tests may lead to delays in effective preventive treatments for high-risk women who have no symptoms, or result in unnecessary medical tests and/or surgery for those who do not have the disease.

<http://www.webmd.com/ovarian-cancer/news/20160909/fda-warns-ovarian-cancer-tests-not-reliable>



IT WAS HARD TO TELL THE  
**McCARTHY TWINS**  
APART. THEY EVEN HAD THE SAME CANCER.

Fortunately, they also had the same hospital: the University of Chicago Medicine. Kelly McCarthy was eight months pregnant when she was diagnosed with stage IIB breast cancer. After her son was born, she underwent chemotherapy, radiation, and surgery to remove her right breast. Just four months later, her identical twin Kristen was diagnosed with stage 0 breast cancer, requiring a double mastectomy followed by reconstructive surgery. Later, when Kelly underwent a second mastectomy and also required reconstruction, **Dr. David Song** transplanted some of Kristen's skin and tissue to create one of Kelly's new breasts. Which is why these twins will tell you the same thing: There's no other medical center like the University of Chicago Medicine. For more information, contact James Bae, Regional Manager of International Programs at [youngjoo.bae@uchospitals.edu](mailto:youngjoo.bae@uchospitals.edu) or call +1-224-315-3948.

AT THE FOREFRONT OF MEDICINE®



**THE UNIVERSITY OF  
CHICAGO MEDICINE**

International Programs